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Zusammenfassung	
Zusammenfassung	
Nierenzellkarzinome	(NZKs)	zählen	weltweit	zu	den	häufigen	Krebsformen	und	sind	
bei	Männern	der	neunthäufigste,	bei	Frauen	der	vierzehnhäufigste	bösartige	Tumor.	
Die	 klarzellige	Histologie	 (kzNZK)	 ist	 der	 häufigste	 Subtyp	 und	macht	 circa	 70-75%	
aller	 Fälle	 aus.	 Die	 Ätiopathogenese	 des	 kzNZK	 ist	 unvollständig	 verstanden,	
gleichwohl	 verschiedene	 Risikofaktoren	 bekannt	 sind.	 Die	 Identifikation	 neuer	
klinischer	 und	 pathologischer	 Marker	 zur	 Diagnosestellung,	 Prognoseabschätzung	
und	 Therapiestratifizierung	 ist	 ein	 entscheidendes	 Ziel,	 um	 mittelfristig	 die	
inbesondere	bei	höheren	Tumorstadien	schlechten	klinischen	Outcomes	des	kzNZK	
zu	 verbessern.	 Interleukin-22	 (IL-22)	 ist	Mitglied	 der	 IL-10	 Zytokinfamilie	 und	wird	
von	verschiedenen	Lymphozytensubsets	produziert.	 IL-22	 spielt	eine	wichtige	Rolle	
für	 die	 Homöostase	 mehrerer	 Organe	 und	 verhindert	 Gewebeschäden	 durch	
Invasion	von	Pathogenen	und	die	vergesellschaftete	Entzündungsreaktion.	Allerdings	
spielt	 IL-22	 auch	 eine	 Rolle	 in	 der	 Pathogenese	 verschiedener	 Karzinome.	 Die	
biologischen	Effekte	von	IL-22	werden	hierbei	durch	Bindung	an	den	heterodimeren	
Transmembran-Rezeptorkomplex	aus	 IL22RA1	und	 IL10R2	vermittelt.	Die	Rolle	 von	
IL-22	und	seinem	Rezeptor	bei	klarzelligem	kzNZK	ist	bisher	unbekannt.	
In	 dieser	 Arbeit	 wurden	 daher	 zunächst	 die	 Effekte	 der	 IL-22-	 und	 IL22RA1-	
RNA-Expression	 auf	 das	 Gesamt	 (OS)-	 und	 das	 Tumor-freie	 (DFS)	 Überleben	 von	
kzNZK-Patienten	 der	 The	 Cancer	 Genome	 Atlas	 (TCGA)–	 Kohorte	 untersucht.	
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Anschließend	 wurden	 zusätzlich	 Gewebeproben	 von	 60	 Patienten	 mit	 nicht	
metastasiertem	kzNZK,	die	an	der	LMU	behandelt	wurden,	immunhistochemisch	auf	
die	Expression	von	 IL-22,	 IL-22RA1,	 IL-22BP,	Ki-67	und	Caspase-3	untersucht.	Diese	
Ergebnisse	wurden,	zusammen	mit	klinisch-pathologischen	Daten,	ebenfalls	mit	dem	
OS	und	DFS	der	Patienten	verglichen.	
Die	 Überexpression	 von	 IL-22	 und	 IL22RA1	 war	 in	 der	 TCGA-Kohorte	 mit	 einem	
signifikant	 kürzeren	 OS	 und	 DFS	 assoziiert.	 Immunhistochemisch	 konnten	 in	 der	
LMU-Kohorte	 jeweils	 in	 einem	 Subset	 der	 Patienten	 IL-22,	 IL-22RA1,	 Ki-67,	 and	
caspase-3	 positive	 Zellen	 nachgewiesen	 werden,	 während	 die	 IL-22BP	 Färbung	 in	
allen	Fällen	negativ	blieb.	Statistische	Analyzen	zeigten,	dass	die	Protein-Expression	
von	IL-22	mit	dem	Fuhrman-Grad,	dem	initialen	T-Stadium,	späterem	Rezidiv	sowie	
dem	Gesamtüberleben	der	kzNZK-Patienten	korrelierten.	Die	Protein-Expression	von	
IL22RA1	 hingegen	 korrelierte	 mit	 Fuhrman-Grad,	 späterem	 Rezidiv	 sowie	 dem	
Gesamtüberleben.	Weiterhin	zeigte	sich	in	der	Kaplan-Meier	Analyze	ein	signifikant	
kürzeres	OS	und	DFS	für	Patienten	mit	Überexpression	von	IL-22,	IL22RA1	und	Ki-67,	
während	die	Überexpression	von	Caspase-3	nur	mit	 einem	kürzeren	DFS	assoziiert	
war.	 Die	 IL22RA1	 Expression	 konnte	 darüber	 hinaus	 in	 einer	 multivariaten	
Cox-Regression	als	unabhängiger	Prediktor	für	OS	und	DFS	identifiziert	werden.	
Zusammenfassend	 zeigt	 diese	 Arbeit	 eine	 Rolle	 der	 IL-22/IL22RA1-Achse	 für	 die	
Prognoseabschätzung	 beim	 kzNZK	 und	 bestätigt	 zusätzlich	 den	 Wert	 der	 Ki-67	
Färbung	in	Hinblick	auf	diese	Fragestellung.
vi	
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Summary	
Renal	cell	carcinoma	is	the	9th	and	the	14th	most	common	cancer	in	men	and	women	
worldwide,	 respectively.	 Clear	 cell	 histology	 is	 the	most	 common	 subtype	of	 renal	
cell	 carcinoma,	which	accounts	 for	about	70-75%	of	all	 cases.	 The	pathogenesis	of	
renal	 cell	 carcinoma	 is	 not	 well	 clarified	 and	 various	 factors	 are	 reported	 to	 be	
associated	 with	 kidney	 cancer.	 Identifying	 novel	 clinical	 and	 pathological	 features	
associated	with	the	diagnosis,	prognosis	and	targeted	therapies	of	ccRCC	patients	is	
an	essential	task.	Interleukin-22	(IL-22)	belongs	to	the	IL-10	family	of	cytokine	and	is	
produced	 by	 several	 subsets	 of	 lymphocytes.	 IL-22	 plays	 an	 important	 role	 in	
sustaining	 the	 integrity	 of	 several	 organs	 and	 it	 prevents	 injury	 due	 to	 invading	
pathogens	 and	 the	 subsequent	 inflammatory	 response.	Moreover,	 IL-22	 has	 been	
reported	 to	 be	 associated	 with	 cancers	 in	 several	 organs.	 IL-22	 mediates	 its	
biological	 effect	 by	 binding	 to	 the	 heterodimeric	 transmembrane	 complex	 of	
IL-22RA1	and	IL-10R2.	
	
In	 the	 present	 study,	 the	 expression	 pattern	 of	 IL-22	 and	 IL-22RA1	 and	 their	
association	with	the	survival	of	ccRCC	patients	from	The	Cancer	Genome	Atlas	were	
analyzed.	Then	60	tumor	samples	from	non-metastatic	ccRCC	patients	were	selected	
for	 IL-22,	 IL-22RA1,	 IL-22BP,	 Ki-67,	 Caspase-3	 immunohistochemical	 staining.	
Afterwards,	staining	evaluation	was	performed,	and	the	patients’	clinicopathological	
vii	
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characteristics	 were	 analyzed	 and	 the	 correlations	 between	 immunohistochemical	
variables	 and	 patients’	 outcome	 were	 assessed.	 From	 the	 TCGA	 analysis	 results,	
patients	 without	 alterations	 in	 IL-22	 or	 IL-22RA1	 had	 a	 significantly	 good	 overall	
survival	 and	 disease-free	 survival	 compared	 to	 patients	with	 alteration	 in	 IL-22	 or	
IL-22RA1.	 Immunohistochemical	 staining	 detected	 IL-22,	 IL-22RA1,	 Ki-67,	 and	
caspase-3	positive	tumor	cells,	but	no	IL-22BP	positive	cell	was	detected.	Statistical	
analysis	showed	that	IL-22	expression	was	correlated	with	Fuhrman	grade,	primary	T	
stage,	 relapse	 and	 vital	 status	 of	 ccRCC	 patients.	 And	 IL-22RA1	 expression	 was	
associated	 with	 Fuhrman	 grade,	 relapse,	 and	 vital	 status	 of	 ccRCC	 patients.	
Moreover,	Kaplan-Meier	analysis	revealed	that	ccRCC	patients	with	high	expression	
of	 IL-22	had	a	poor	overall	 survival	and	disease-free	 survival	 compared	 to	patients	
with	 low	 expression	 of	 IL-22.	 This	was	 true	 also	 for	 IL-22RA1	 and	 Ki-67.	 However,	
ccRCC	patients	with	 high	 expression	of	 caspase-3	only	 showed	 a	 significantly	 poor	
disease-free	 survival,	 but	 not	 overall	 survival.	 In	 addition,	 multivariable	 Cox	
proportional	 hazards	 regression	 model	 showed	 that	 tumor	 stage,	 presence	 of	
necrosis	 in	 tumor,	 and	 IL-22RA1	 probably	 are	 independent	 predictors	 for	 overall	
survival	 of	 ccRCC	 patients,	 and	 Fuhrman	 grade,	 tumor	 stage,	 presence	 of	 venous	
thrombus	and	IL-22RA1	are	independent	predictors	of	disease-free	survival	of	ccRCC	
patients.	Several	conclusions	can	be	drawn:	the	IL-22-IL-22RA1	axis	is	correlated	with	
several	 clinicopathological	 characteristics	 such	 as	 Fuhrman	 grade,	 primary	 T	 stage,	
relapse	and	vital	status	of	ccRCC	patients;	ccRCC	patients	with	lower	expression	level	
of	IL-22,	IL-22RA1,	Ki-67	tend	to	have	a	longer	survival	time;	IL-22RA1	but	not	IL-22,	
viii	
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is	an	independent	predictive	factor	for	prognosis	of	ccRCC	patients.
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Introduction	
1. Introduction	
1.1	Renal	cell	carcinoma	
1.1.1	Epidemiology	 	
Currently,	 renal	cell	carcinoma	 is	 the	9th	and	the	14th	most	common	cancer	 in	men	
and	 women	 worldwide	 respectively.	 In	 the	 year	 2012,	 the	 estimated	 amount	 of	
deaths	from	renal	cancer	was	143,000,	which	ranked	the	16th	most	common	cause	of	
death	from	metastatic	disease	worldwide.	(Znaor,	Lortet-Tieulent	et	al.	2015)	Among	
all	human	malignant	diseases,	2-3%	are	renal	cell	carcinomas	(RCC),	which	account	
for	approximately	90%	of	all	primary	malignancies	of	the	kidney.	Despite	the	advent	
of	improved	diagnostic	methods,	particularly	imaging	techniques,	around	20-30%	of	
all	 patients	have	metastatic	disease	at	 the	 time	of	diagnosis.	 (Rini,	 Campbell	 et	 al.	
2009)	(Ljungberg,	Campbell	et	al.	2011)	The	incidence	of	renal	cell	carcinoma	varies	
in	 different	 areas	 of	 the	world,	 and	 is	 higher	 in	 developed	 countries	 compared	 to	
developing	countries.	Men	seem	more	likely	to	suffer	from	renal	cancer	than	women,	
with	 the	male	 to	 female	 ratio	 being	 1.5:1.	 (Levi,	 Ferlay	 et	 al.	 2008)	 Incidences	 of	
renal	cancer	 increase	with	age	and	reach	a	plateau	 in	 the	7th	decade	of	 life	 (Chow	
and	Devesa	2008).	 	
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1.1.2	Classification	
Renal	cell	carcinoma	is	not	a	single	disease,	but	rather	a	combination	of	related,	yet	
different	 malignancies	 of	 various	 histological	 subtypes	 that	 arise	 from	 the	 renal	
tubule	cell	(Larkin,	Goh	et	al.	2012),	and	different	histologic	subtypes	are	believed	to	
originate	 from	different	 parts	 of	 the	 nephron	 (Shuch,	 Amin	 et	 al.	 2015).	 Clear	 cell	
renal	 cell	 carcinoma	 (ccRCC)	 accounts	 for	 about	 70-75%	 of	 kidney	 cancer,	 and	
therefore	 is	 the	most	 common	 subtype	of	 this	 cancer.	 Papillary	RCC	 is	 the	 second	
most	 common	 subtype	of	 kidney	 cancer,	 accounting	 for	 around	10-16%	of	 all	 RCC	
cases.	Papillary	RCC	can	further	be	divided	into	2	different	subtypes,	papillary	type	1	
and	papillary	type	2	(Srigley	and	Delahunt	2009).	The	third	most	common	subtype	of	
renal	 cell	 carcinoma	 is	 chromophobe	 RCC,	 and	 accounts	 for	 5%	 of	 all	 RCC	 cases	
(Shuch,	Amin	et	al.	2015).	Collecting	duct	RCC	is	considered	to	arise	from	the	kidney	
medulla	 and	 only	 accounts	 for	 <0.5%	 cases	 of	 RCC	 (Fleming	 and	 Lewi	 1986).	
Medullary	RCC	is	an	extremely	rare	subtype	with	a	poor	survival,	many	patients	die	
within	 months	 after	 diagnosis.	 It	 is	 recognised	 as	 a	 tumor	 arising	 from	 calyceal	
epithelium	or	papillae	and	possibly	be	initiated	by	chronic	medullary	hypoxia	caused	
by	 hemoglobinopathy.	 (Davis,	 Mostofi	 et	 al.	 1995)	 (Swartz,	 Karth	 et	 al.	 2002)	 In	
addition,	 there	 are	 several	 other	 RCC	 forms	 associated	 with	 specific	 genes,	 like	
“microphthalmia	transcription	factor	family”-translocation	RCC	as	well	as	hereditary	
renal	cell	carcinoma	syndromes.	(Shuch,	Amin	et	al.	2015)	
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1.1.3	Pathogenesis	
The	pathophysiology	linking	risk	factors	with	RCC	is	still	not	completely	understood.	
Etiologic	factors	involve	many	aspects,	among	which	specific	lifestyle	is	likely	to	play	
an	 important	 role	 in	 the	 development	 of	 RCC.	 Cigarette	 smoking,	 both	 active	 or	
passive,	 is	 an	 established	 risk	 factor	 for	 kidney	 cancer,	 and	 the	 risk	 compared	 to	
non-smokers	increases	about	50%	in	male	and	20%	in	female	smokers	(Hunt,	van	der	
Hel	et	al.	2005).	Excessive	body	weight	is	also	a	potential	risk	factor,	with	RCC	being	
a	 cancer	 type	 robustly	 associated	with	 increased	Body-mass	 index	 (BMI),	 probably	
because	 the	 adipose	 tissue	 can	 provide	 an	 abundant	 energy	 source	 for	malignant	
lesions	of	the	kidney	to	escape	the	immune	system,	to	grow	and	to	form	metastases	
(Gati,	 Kouidhi	 et	 al.	 2014).	 Rohrmann	 et	 al.	 studied	 the	 relationship	 between	
consumption	of	meat	and	fish	with	the	risk	of	RCC	and	they	showed	an	association	
between	 red	 and	 processed	 meat	 consumption	 and	 the	 risk	 of	 kidney	 cancer	 in	
women	 (Rohrmann,	Linseisen	et	al.	2015).	 In	addition,	a	pooled	analysis	of	 several	
cohort	 studies	 showed	 a	 negative	 correlation	 between	 kidney	 cancer	 and	 diets	
abundant	 in	 fruits	and	vegetables	 (Lee,	Mannisto	et	al.	2009).	A	cohort	study	from	
Sweden	 indicated	 that	 the	 risk	 for	 RCC	 development	 increased	 with	 elevation	 of	
blood	pressure	and	decreased	with	reducing	elevated	blood	pressure	(Chow,	Gridley	
et	al.	2000),	suggesting	hypertension	is	another	risk	factor	for	RCC.	In	spite	of	the	risk	
factors	mentioned	above,	 still	many	RCC	patients	do	not	have	any	 identifiable	 risk	
factor.	In	addition,	patients	with	end	stage	renal	disease	(ESRD)	requiring	dialysis	are	
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at	risk	for	developing	kidney	cancer	(Maisonneuve,	Agodoa	et	al.	1999).	
	
Approximately	 2-3%	 of	 renal	 cell	 carcinomas	 are	 familial	 (Lipworth,	 Tarone	 et	 al.	
2006).	The	risk	to	suffer	RCC	is	nearly	two-fold	increased	for	a	first	grade	relative	of	a	
kidney	 cancer	 patient	 (Ljungberg,	 Campbell	 et	 al.	 2011),	 suggesting	 one	 ore	more	
genetic	risk	factors.	A	two-stage	genome-wide	association	study	of	RCC	by	a	research	
group	 led	 by	 International	 Agency	 for	 Research	 on	 Cancer	 and	 the	 US	 National	
Cancer	 Institute	 showed	 that	 two	 genetic	 loci	 (2p21	 [EPAS1]	 and	 11q13.3	 [no	
characterized	genes])	were	associated	with	RCC	susceptibility	(Purdue,	Johansson	et	
al.	 2011).	 It	 provides	 evidence	 that	 genetics	 can	 affect	 susceptibility	 to	 renal	 cell	
carcinoma.	
	
1.1.4	Molecular	pathways	of	clear	cell	renal	cell	carcinoma	
The	 prognosis	 associated	 with	 RCC	 differs	 among	 subtypes,	 but	 there	 is	 also	
considerable	outcome	variability	within	the	same	subtype.	The	clinical	outcomes	of	
ccRCC	are	 influenced	by	several	prognostic	 factors	 including	tumor	stage,	Fuhrman	
grade,	 as	 well	 as	 the	 presence	 of	 necrosis	 (Frank,	 Blute	 et	 al.	 2002,	 Delahunt,	
McKenney	et	al.	2013).	 	
	
So	 far,	 several	 biomarkers	 have	 been	 considered	 as	 potential	 prognostic	markers.	
However,	 none	 of	 them	 have	 been	 adopted	 in	 clinical	 care.	 The	 molecular	
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mechanisms	 contributing	 to	 the	 development	 of	 RCC	 have	 not	 been	 understood	
completely.	CSNK2A1	 (Casein	Kinase	2	Alpha	1),	SPP1	 (Secreted	Phosphoprotein	1)	
as	well	as	DEFB1	(Defensin	Beta	1)	are	three	new	identified	genes,	there	is	significant	
association	between	high	expression	and	a	poor	outcome	in	ccRCC	patients	(Rabjerg,	
Bjerregaard	 et	 al.	 2016).	 ccRCC	 originates	 from	 proximal	 convoluted	 tubules	 in	
nephrons	 and	 is	 associated	 with	 a	 mutation	 and/or	 inactivation	 of	 the	 von	
Hippel-Lindau	(VHL)	gene	and	activation	of	the	Raf-MAPK	(mitogen-activated	protein	
kinase)-ERK	(extracellular	signal-regulated	kinases)	pathway	(Wong,	Ojo	et	al.	2015).	
The	 current	 therapies	 include	 agents	 that	 target	 the	 vascular	 endothelial	 growth	
factor	(VEGF)	pathway	or	mammalian	target	of	rapamycin	(mTOR)	(Singer,	Gupta	et	
al.	 2013).	 The	 VHL-hypoxia-inducible	 factor	 (HIF)	 pathway	 also	 plays	 an	 important	
role	 in	 ccRCC	 (Latif,	 Tory	 et	 al.	 1993).	 In	 up	 to	 41%	 of	 ccRCC	 tumors	 there	 are	
mutations	 in	 the	 Polybromo	 1(PBRM1)	 gene,	 which	 is	 located	 on	 3p21,	 making	
PBRM1	one	 of	 the	most	 commonly	mutated	 genes	 in	 ccRCC,	 ranking	 second	 after	
VHL	(Varela,	Tarpey	et	al.	2011)..	Several	studies	including	The	Cancer	Genome	Atlas	
(TCGA)	 project	 (found	 BAP1	 (BRCA1	 associated	 protein	 1)	 alterations	 in	 8-10%	 of	
ccRCC	 (Guo,	 Gui	 et	 al.	 2012,	 Cancer	 Genome	 Atlas	 Research	 2013).	 Mutations	 in	
BAP1	and	PBRM1	are	associated	with	pathology	characters	such	as	tumor	grade	and	
sarcomatoid	variants,	biology	as	well	as	prognosis	(Su,	Singer	et	al.	2015).	Mutations	
in	PTEN	(Phosphatase	and	tensin	homolog)	and	mTOR	were	present	in	4%	and	6%	of	
ccRCC,	 respectively(Cancer	 Genome	 Atlas	 Research	 2013).	 Novel	 targeted	
immunotherapy	such	as	PD-1	(programmed	death	1)	and	PD-L1	(programmed	death	
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ligand	1)	targeted	agents	have	been	developed.	Previous	studies	revealed	that	PD-L1	
expression	 is	 correlated	 with	 a	 poor	 outcome	 in	 RCC	 mostly	 because	 of	 its	
immunosuppressive	function	(Thompson,	Gillett	et	al.	2004,	Thompson,	Kuntz	et	al.	
2006,	Choueiri,	 Fishman	et	al.	2016).	PD-1	 from	T	cell	binding	 to	PD-L1	 from	renal	
cancer	 cell	 blocks	 the	 immune	 response	 such	 as	 inhibiting	 cytokine	 release	 and	
antitumor	 T	 cells	 activity	 (Harshman,	 Drake	 et	 al.	 2014).	 Figure	 1	 summarizes	 the	
pathways	in	renal	cell	carcinoma.	 	
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Figure	1	Pathways	in	renal	cell	carcinoma.	An	endothelial	cell,	a	renal	cancer	cell	and	a	T	cell	
are	 show.	 Accumulated	 HIF	 translocates	 into	 the	 nucleus	 of	 renal	 cancer	 cell	 after	 the	
mutation	 of	 VHL,	 following	 by	 activation	 of	 HIF	 target	 genes	 including	 VEGF,	 VEGFR,	 FGF	
(fibroblast	 growth	 factor),	 FGFR	 (FGF	 receptor),	 PDFG	 (platelet	derived	growth	 factor)	 and	
PDFGR	(PDFG	receptor).	PD-1	binding	to	PD-L1	blocks	the	immune	response	between	T	cell	
and	cancer	cell.	Cell	signaling	factor	activates	PI3K-AKT-mTOR	pathway,	 leading	to	anabolic	
effects	in	renal	cancer	cell.	(Choueiri	and	Motzer	2017)	
	
Ki-67	 is	 a	 well-established	 marker	 of	 tumor	 cell	 proliferation.	 The	 association	
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between	Ki-67	staining	indices	and	outcome	of	cancer	is	a	continuous	function,	the	
higher	 the	 score,	 the	 greater	 the	 risk	 of	 biochemical	 or	 clinical	 failure	 (Pollack,	
DeSilvio	et	al.	2004).	One	of	 the	 largest	studies	 indicated	that	patients	with	higher	
expression	 of	 Ki-67	 were	more	 likely	 to	 die	 because	 of	 RCC	 and	 that	 Ki-67	 had	 a	
significant	 relationship	 with	 adverse	 pathological	 features	 of	 RCC	 (Tollefson,	
Thompson	et	al.	2007).	
	
Caspase-3	(also	known	as	CPP32,	YAMA,	and	apopain)	 is	an	apoptosis-related	gene	
located	at	4q35.1	(Yan,	He	et	al.	2013).	Caspase-3	acts	as	an	effector	in	the	caspase	
apoptotic	 cascade.It	 can	 be	 activated	 by	 the	mitochondrial	 or	 the	 death	 receptor	
apoptotic	 pathway	 (Soung,	 Lee	 et	 al.	 2004,	 Chen,	 Zhao	 et	 al.	 2008,	 Kuo,	 Yu	 et	 al.	
2011,	Onouchi,	Suzuki	et	al.	2013).	The	normal	apoptotic	process	can	be	inhibited	by	
the	 activation	 of	 caspase3,	 and	 deregulations	 of	 apoptotic	 pathways	 can	 increase	
cell	 survival	 in	 a	 lot	 of	 cancers,	 and	 may	 further	 support	 anchorage-independent	
survival	 during	 the	 process	 of	 metastasis	 (Frisch	 and	 Francis	 1994,	 Glinsky	 and	
Glinsky	 1996,	 Takaoka,	 Adachi	 et	 al.	 1997).	 However,	 several	 cancers	 showed	
significantly	lower	expression	of	the	caspase3	protein	compared	to	the	expression	in	
normal	 tissues	 (Hosgood,	Baris	et	al.	2008,	Kinslow,	El-Zein	et	al.	2008).	One	study	
indicated	 that	 gene	 polymorphisms	 and	 haplotypes	 of	 caspase3	 increased	 the	 risk	
for	gastric	cancer	(Li,	Liu	et	al.	2014).	Another	study	provided	evidence	that	caspase3	
expression	 in	 metastatic	 lymph	 nodes	 can	 be	 a	 potential	 independent	 prognostic	
factor	 of	 shorter	 overall	 survival	 in	 esophageal	 squamous	 cell	 carcinoma	 patients	
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with	 lymph	 nodes	 metastasis	 (Wang,	 Luo	 et	 al.	 2014).	 However,	 the	 correlation	
between	caspase3	and	outcome	of	RCC	has	not	been	established	from	the	literature.	 	
	
Advanced	ccRCC	 is	 still	 an	 incurable	disease	with	a	poor	prognosis.	Without	doubt	
there	 is	 an	 increasing	 need	 for	 the	 identification	 of	 biomarkers	 that	 may	 predict	
ccRCC	recurrence	and	survival.	 	
	
1.1.5	Therapy	of	clear	cell	renal	cell	carcinoma	
Radical	 nephrectomy	 and	 partial	 nephrectomy	 are	 the	 only	 curative	 options	 for	
nonmetastatic	clear	cell	renal	cell	carcinoma,	and	surgery	is	also	an	important	option	
to	relieve	symptoms	from	metastatic	ccRCC	(mccRCC).	Surgical	 resection	should	be	
used	 in	 combination	with	 systemic	 therapy	 for	 the	 patients	 with	mccRCC.(Biswas,	
Kelly	 et	 al.	 2009)	 	 ccRCC	 is	 resistant	 to	 radiotherapy	 or	 chemotherapy,	 and	while	
high-dose	 interleukin-2	or	 interferon-alfa	may	 induce	durable	 responses	 in	 a	 small	
percentage	 of	mccRCC	 patients,	 the	 therapy	 is	 toxic	 and	 only	 suitable	 for	 a	 small	
patient	population	 (Keizman,	Maimon	et	al.	2015).	VEGF-TKIs	 (Sorafenib,	Sunitinib)	
and	 mTOR	 inhibitors	 (Everolimus,	 Temsirolimus)	 are	 used	 as	 first	 line	 treatment	
options	for	patients	with	mccRCC.	Second	line	or	later	options	include	axitinib,	which	
is	 an	 inhibitor	 of	 VEGFRs	 and	 cabozantinib,	 an	 inhibitor	 of	 VEGFRs,	MET,	 and	 AXL	
(Choueiri	and	Motzer	2017).	Recently,	monoclonal	antibodies	(Nivolumab)	targeting	
and	 blocking	 the	 inhibitory	 T-cell	 receptor,	 PD-1	 and	 its	 ligand	 PD-L1	 emerged	 as	
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promising	therapy	for	mccRCC	(Shin,	Jeon	et	al.	2015).	
	
1.2	Interleukin-22	 	
1.2.1	Introduction	of	IL-22	
Interleukin-22	(IL-22)	is	a	member	of	the	IL-10	cytokine	family	along	with	IL-19,	IL-20,	
IL-24,	 IL-26	 and	 IL-28	 (α	 and	 β).	 It	 is	 produced	 by	 several	 subsets	 of	 lymphocytes	
including	CD4+	T	helper	17	(Th17)	cells	 (also	known	as	 IL-17-producing	cells,	which	
are	considered	as	a	key	cellular	source	of	IL-22)	(Ouyang,	Rutz	et	al.	2011)	and	Th22	
cells,	 CD8+	 cytotoxic	 T	 cells,	 natural	 killer	 (NK)	 cells,	 γδT	 cells	 and	 lymphoid	 tissue	
inducer	(LTi)-like	cells	(Lim	and	Savan	2014).	Of	the	CD4+	T	cells,	Th17	and	Th22	cells	
are	 the	major	 sources	 of	 IL-22.	 Th1	 cells	 can	 also	 produce	 IL-22	 (Gurney	 2004).	 In	
humans,	 IL-22	 is	mostly	 produced	 by	 Th1,	 Th17	 and	 Th22	 cells.	 However,	murine	
IL-22	is	mainly	produced	by	Th17	cells	(Zheng,	Danilenko	et	al.	2007,	Duhen,	Geiger	
et	al.	2009,	Eyerich,	Eyerich	et	al.	2009,	Volpe,	Touzot	et	al.	2009).	What	should	be	
paid	 attention	 to	 is,	 that	 the	 principal	 cellular	 sources	 of	 IL-22	 obviously	 vary	
between	tissues,	so	 in	different	kinds	of	tumors,	the	regulation	of	 IL-22	production	
may	involve	different	immune	cell	populations	(Lim	and	Savan	2014).	 	
	
The	human	 IL-22	gene	 is	 located	on	chromosome	12p15,	while	 the	mouse	and	 rat	
genes	are	located	on	chromosomes	10	and	7,	respectively	(Weidenbusch,	Rodler	et	
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al.	 2015).	 The	 human	 IL-22	 protein	 consists	 of	 146	 amino	 acids	 and	 has	 80.8%	
identity	with	murine	IL-22,	and	IL-22	also	has	an	α-helical	secondary	structure	just	as	
other	family	members	of	IL-10	(Wolk	and	Sabat	2006).	IL-22	normally	plays	a	role	in	
sustaining	 the	 integrity	 as	well	 as	 the	 barrier	 function	of	 these	organs,	 preventing	
injury	from	either	invading	pathogens	or	an	inflammatory	response	(Witte,	Witte	et	
al.	2010,	Sonnenberg,	Fouser	et	al.	2011,	Zenewicz	and	Flavell	2011).	In	this	process,	
IL-22	will	create	pro-inflammatory	epithelial	resist	mechanisms	which	are	crucial	for	
host	protection,	however,	if	this	process	is	not	well	regulated,	inflammation	will	be	
amplified	by	IL-22	alone	or	together	with	other	cytokines,	therefore	inducing	deviant	
epithelial	 proliferation	 as	 well	 as	 differentiation	 (Rutz,	 Eidenschenk	 et	 al.	 2013).	
There	 are	 three	 different	 ways	 in	 which	 IL-22	 functions	 in	 host	 defense	 and	
protection:	 first,	during	 the	 invasion	of	pathogens,	 IL-22	may	help	 to	maintain	and	
rebuild	 the	 epithelial	 barrier	 after	 epithelial	 injury;	 second,	 IL-22	may	 induce	 host	
defense	antimicrobial	protein	expression	together	with	other	cytokines	like	IL-17	or	
tumor	 necrosis	 factor-	 α	 (TNF-α);	 third,	 IL-22	 may	 enhance	 the	 expression	 of	
inflammatory	 mediators	 such	 as	 IL-6,	 IL-1β,	 granulocyte	 colony-stimulating	 factor	
(G-CSF),	 lipopolysaccharide	 (LPS)-binding	 protein	 (LBP)	 and	 serum	amyloid	A	 (SAA)	
(Wolk,	Witte	et	al.	2006,	Boniface,	Guignouard	et	al.	2007,	Aujla,	Chan	et	al.	2008,	
Liang,	Nickerson-Nutter	et	al.	2010).	
	
Additionally,	 IL-22	 also	 contributes	 to	 tissue	 regeneration	 and	 the	 promotion	 of	
wound	healing.	IL-22	may	promote	proliferation	and	survival	of	the	epithelial	cell	in	
12	
Introduction	
many	organs	such	as	intestine,	liver,	thymus	and	lung	(Ki,	Park	et	al.	2010,	Dudakov,	
Hanash	 et	 al.	 2012,	 Kong,	 Feng	 et	 al.	 2012).	 IL-22	 may	 also	 promote	 liver	 cell	
regeneration	 after	 hepatic	 injury.	 There	 are	 anti-apoptotic	 genes	 in	 hepatocytes	
which	can	protect	hepatocytes	from	cell	death	caused	by	inflammation.	Interestingly,	
expression	 of	 these	 genes	 can	 be	 induced	 by	 IL-22	 (Radaeva,	 Sun	 et	 al.	 2004).	
Meanwhile,	IL-22	has	a	protective	role	in	some	other	inflammatory	diseases	and	the	
development	 of	 fibrosis,	 such	 as	 allergic	 airway	 inflammation,	 autoimmune	
myocarditis,	 uveitis	 and	pulmonary	 fibrosis	 (Chang,	Hanawa	et	 al.	 2006,	 Simonian,	
Wehrmann	et	al.	2010,	Ke,	Sun	et	al.	2011,	Nakagome,	Imamura	et	al.	2011)	 	
	
1.2.2	IL-22	receptor	and	IL-22	binding	protein	
The	 IL-22	 receptor	 (IL-22R)	 is	 a	member	 of	 class	 II	 cytokine	 receptor	 family.	 IL-22	
plays	its	role	via	binding	to	the	heterodimeric	transmembrane	complex	iof	IL-22RA1	
and	IL-10R2	(IL-10RB)	(Xin,	Namaka	et	al.	2015).	The	human	gene	encoding	IL-22RA1	
is	located	at	chromosome	1p36.11,	whereas	the	gene	encoding	IL-10R2	is	located	on	
chromosome	 21q22.11	 (Xie,	 Aggarwal	 et	 al.	 2000).	 IL-22RA1	 was	 found	 to	 have	
restricted	 expression	 on	 cells	 of	 epithelial	 origin	 in	 various	 kinds	 of	 non-immune	
tissues	such	as	the	pancreas,	skin	and	colonic	mucosa,	followed	by	kidney,	lung	and	
liver.	(Tachiiri,	Imamura	et	al.	2003,	Wolk,	Kunz	et	al.	2004)	On	the	contrary,	IL-10R2	
is	believed	to	be	expressed	ubiquitously	in	immune	cells	such	as	T	cells,	B	cells	and	
NK	cells,	as	well	as	epithelial	cells	(Wolk,	Kunz	et	al.	2004).	 	
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In	 addition	 to	 the	membrane-bound	 IL-22R,	 there	 is	 a	 soluble	 receptor,	 IL-22RA2,	
also	known	as	IL-22	binding	protein	(IL-22BP)	(Weiss,	Wolk	et	al.	2004,	Sabat	2010,	
Sabat,	 Ouyang	 et	 al.	 2014).	 The	 gene	 encoding	 human	 IL-22BP	 is	 located	 at	
chromosome	 6q23.3	 and	 is	 closeto	 genes	 encoding	 the	 IFN	 (Interferon)-γR	 and	
IL-20R	 (Gruenberg,	Schoenemeyer	et	al.	2001,	Kotenko,	 Izotova	et	al.	2001,	Weiss,	
Wolk	 et	 al.	 2004).	 IL-22BP	 binds	 to	 IL-22	 with	 a	 higher	 affinity	 and	 specificity	
compared	 to	 IL-22RA1	 (20-to1000-fold	 higher)	 (Wolk,	 Witte	 et	 al.	 2007,	 Jones,	
Logsdon	 et	 al.	 2008),	 acts	 as	 a	 decoy	 receptor	 and	 inhibits	 the	 effects	 of	 the	
interaction	between	IL-22	with	its	trans-membrane	receptor	complex	(Sabat,	Ouyang	
et	al.	2014).	Interestingly,	IL-22BP	specifically	binds	to	IL-22,	but	not	other	cytokines	
of	the	IL-10	family	(Dumoutier,	Lejeune	et	al.	2001,	Kotenko,	Izotova	et	al.	2001,	Xu,	
Presnell	 et	 al.	 2001,	 Wei,	 Ho	 et	 al.	 2003).	 Therefore	 IL-22BP	 has	 been	 used	 as	 a	
competitive	 antagonist	 of	 IL-22	 signaling	 in	 vitro	 (Lim	 and	 Savan	 2014).	 IL-22BP	 is	
expressed	 at	 a	 highest	 level	 in	 placenta	 and	mammary	 gland,	 at	 an	 intermediate	
level	 in	 stomach,	 thymus,	 spleen,	 lung,	 skin	 and	 lymph	 nodes,	 and	 expressed	
modestly	 in	 peripheral	 blood	 leucocytes,	 heart,	 brain	 and	 prostate	 (Dumoutier,	
Lejeune	et	al.	2001,	Kotenko,	Izotova	et	al.	2001,	Xu,	Presnell	et	al.	2001,	Wei,	Ho	et	
al.	2003,	Weiss,	Wolk	et	al.	2004).	(Figure	2)	
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Figure	 2	 Principles	 of	 IL-22	 signaling.	 IL-22	 activates	 cellular	 responses	 by	 combining	 to	
receptor	IL-22RA1	and	IL-10Rβ2.	IL-22	binds	to	IL-22RA1	with	high	affinity	but	no	affinity	for	
IL-10Rβ2	 .	After	binding	 to	 IL-22RA1,	 the	 conformation	of	 IL-22	 changes,	 leads	 to	a	 strong	
affinity	 towards	 IL-10Rβ2.	 This	 combination	 phosphorylates	 JAK1	 (Janus	 kinase),	 TYK2	
(Tyrosine	Kinase	2)	and	STAT3	(Signal	transducer	and	activator	of	transcription	3),	therefore	
impact	 downstream	 signaling.	 IL-22BP	 inhibits	 effects	 of	 IL-22	 via	 a	 higher	 affinity	 than	
IL-22RA1	(Weidenbusch,	Rodler	et	al.	2015).	
	
1.2.3	IL-22-IL-22RA1	axis	in	the	kidney	
Initial	 studies	 on	 the	 expression	 of	 IL-22R	 identified	 low	 expression	 in	 the	 kidney	
(Aggarwal,	Xie	et	al.	2001,	Kotenko,	Izotova	et	al.	2001,	Tachiiri,	Imamura	et	al.	2003,	
Wolk,	Kunz	et	al.	2004),	whereIL-22R	is	mainly	expressed	on	tubular	epithelial	cells	
(Kulkarni,	Hartter	et	al.	2014).	So	far,	little	is	known	about	the	function	of	IL-22	in	the	
kidney.	 According	 to	 a	 previous	 study,	 IL-22	 will	 be	 induced	 in	 the	 kidney	 after	
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stimulation	 by	 DAMPs	 (Kulkarni,	 Hartter	 et	 al.	 2014)	 and	 it	 also	 can	 be	 seen	 in	 a	
polymicrobial	 peritonitis	 model	 (Weber,	 Schlautkotter	 et	 al.	 2007).	 IL-22	 was	
believed	to	function	against	the	regeneration	of	the	kidney	because	of	the	fact	that	
blockade	 of	 IL-22	 by	 IL-22BP-Fc	 can	 relieve	 renal	 damage	 and	 increase	 bacterial	
clearance	from	the	kidney	 in	polymicrobial	peritonitis	 (Dumoutier,	Van	Roost	et	al.	
2000,	Weber,	 Schlautkotter	 et	 al.	 2007).	Moreover,	 one	 study	 found	 a	 correlation	
between	polymorphisms	in	the	IL-22R	and	nephropathy	development	(Suh,	Cho	et	al.	
2013).	One	 study	 focused	on	 IL-22BP	demonstrated	 that	urinary	 IL-22BP	 levels	are	
correlated	 with	 active	 renal	 disease	 and	 IL-22BP	 is	 highly	 expressed	 in	 the	 renal	
tissue	of	patients	with	 	 active	renal	disease,	(Yang,	Gao	et	al.	2014).	 	
	
1.2.4	Signaling	pathways	of	IL-22	
The	assembly	of	the	 IL-22-IL-22R1-IL-10R2	complex	activates	Janus	tyrosine	kinases	
(Jak1	 and	 Tyk2)	 associated	 with	 the	 receptor	 complex,	 which	 results	 in	 the	
phosphorylation	 of	 these	 receptors	 as	 well	 as	 signal	 transducer	 and	 activator	 of	
transcription	 (STAT)	 	 proteins	 (Dudakov,	 Hanash	 et	 al.	 2015).	 Phosphorylation	 of	
STAT3	is	believed	to	be	the	primary	mediator	of	IL-22	signaling.	However,	STAT1	and	
STAT5	phosphorylation	have	also	been	found	to	play	a	role	(Lejeune,	Dumoutier	et	al.	
2002,	 Wolk,	 Kunz	 et	 al.	 2004).	 In	 addition,	 IL-22	 activates	 the	 mitogen-activated	
protein	 kinase	 (MAPK)	 pathway	 including	 extracellular	 signal-regulated	 kinase	 1/2	
(ERK1/2),	 c-Jun	 N-terminal	 kinase	 (JNK)	 and	 p38	 (Lejeune,	 Dumoutier	 et	 al.	 2002,	
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Brand,	Dambacher	et	al.	2007,	Lim	and	Savan	2014)as	well	as	phosphatidylinositide	
3-Kinase-Akt-mammalian	 target	 of	 rapamycin	 (PI3K-Akt-mTOR)	 pathway	 (Mitra,	
Raychaudhuri	et	al.	2012,	Sabat,	Ouyang	et	al.	2014).	.	STAT3	phosphorylation	is	an	
important	 downstream	 pathway	 in	 terms	 of	 regulating	 the	 effect	 of	 IL-22	 in	
epithelial	cells,	and	research	on	chemical-induced	colitis	indicated	IL-22	-dependent	
phosphorylation	 of	 STAT3	 in	 	 epithelial	 cells;	 meanwhile,	 conditional	 deletion	 of	
STAT3	 in	 vivo	 in	 intestinal	 epithelial	 cells	 led	 to	 a	 similar	 phenotype	 seen	 in	 IL-22	
deficient	mice	after	chemical-induced	colitis.	This	demonstrates	an	essential	role	for	
STAT3	in	IL-22	mediated	signaling	(Pickert,	Neufert	et	al.	2009).	 	
	
1.2.5	IL-22	in	inflammatory	diseases	
IL-22	 is	 expressed	 in	 a	 wide	 range	 of	 organs	 such	 as	 skin,	 liver,	 breast,	 thymus,	
kidney,	lung,	pancreas,	gastrointestinal	tract,	heart,	eye,	synovial	tissues	and	adipose	
tissue,	 and	 its	 receptor	 is	 expressed	 on	 the	 stromal	 and	 epithelial	 cells	 of	 those	
organs	 (Witte,	 Witte	 et	 al.	 2010,	 Sonnenberg,	 Fouser	 et	 al.	 2011,	 Cordero-Coma,	
Calleja	 et	 al.	 2013,	 Sabat,	 Ouyang	 et	 al.	 2014,	 Dudakov,	 Hanash	 et	 al.	 2015).	 As	
mentioned	 above,	 IL-22	 is	 produced	 at	 sites	 of	 inflammation,	 therefore	 it	may	 be	
involved	 in	 regulating	a	physiological	 response	 to	 repair	 tissue	damage,	but	 it	may	
also	 lead	 to	 pathological	 inflammation	 (Dudakov,	 Hanash	 et	 al.	 2015).	 There	 are	
several	 experimental	 models	 showing	 that	 IL-22	 may	 play	 a	 protective	 role	 by	
regenerating	 epithelial	 tissues	 including	 pancreatitis,	 thymic	 injury,	 colitis	 and	
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hepatitis	(Witte,	Witte	et	al.	2010,	Sonnenberg,	Fouser	et	al.	2011,	Dudakov,	Hanash	
et	al.	2012).	However,	IL-22	has	been	reported	to	induce	proinflammatory	molecule	
expression,	 such	 as	 IL-1,	 IL-6,	 IL-8,	 IL-11,	 G-CSF,	 GM-CSF	 and	 LPS	 binding	 protein	
(Andoh,	Zhang	et	al.	2005,	Sonnenberg,	Fouser	et	al.	2011,	Mortha,	Chudnovskiy	et	
al.	 2014).	 Tissue	 damage	 disrupts	 tissue	 homeostasis	 and	 induces	 responses	 that	
intend	to	eliminate	the	injurious	trigger	and	try	to	reinstall	tissue	homeostasis	 such	
as	 inflammation,	 atrophy	 and	 fibrosis	 (Hagemann,	 Haegele	 et	 al.	 2013,	
Suarez-Alvarez,	 Liapis	 et	 al.	 2016).	 Notch	 signalling	 is	 known	 to	 mediate	
development	as	well	as	homeostasis	 in	various	organs	including	kidney,	heart,	 lung	
and	 intestine,	 and	 plays	 a	 main	 role	 in	 immune	 homeostasis	 as	 well	 (Radtke,	
Fasnacht	et	al.	2010,	Barak,	Surendran	et	al.	2012,	Xu,	Moghal	et	al.	2012,	Radtke,	
MacDonald	 et	 al.	 2013,	 Tsai,	 VanDussen	 et	 al.	 2014,	 Luxan,	 D'Amato	 et	 al.	 2016).	
Several	 studies	 found	a	correlation	between	Notch	and	 IL-22,	 that	Notch	signalling	
induces	 IL-22	 production	 by	 aryl	 hydrocarbon	 receptor	 ligands	 and	 in	 vivo	 the	
production	of	IL-22	is	mediated	by	Notch	signalling	(Alam,	Maekawa	et	al.	2010,	Lee,	
Cella	et	al.	2012).	 In	conclusion,	 IL-22	 is	 involved	 in	tissue	homeostasis	and	plays	a	
role	in	inflammation,	atrophy	and	fibrosis	via	Notch	signalling.	 	
	
1.2.6	IL-22	in	autoimmune	diseases	
Studies	 have	 shown	 that	 some	 inflammatory	 cytokines	 are	 involved	 in	 the	
pathogenesis	of	autoimmune	disease	(Pan,	Li	et	al.	2013).	IL-17	was	believed	to	play	
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a	 pathogenic	 role	 in	 autoimmunity	 (Pan,	 Ye	 et	 al.	 2008).	 Several	 research	 groups	
indicated	that	 increased	IL-17	levels	are	correlated	with	many	chronic	autoimmune	
diseases	 such	 as	 systemic	 lupus	 erythematosus,	 rheumatoid	 arthritis,	 multiple	
sclerosis,	psoriasis	and	Sjögren’s	syndrome	(Garrett-Sinha,	John	et	al.	2008,	van	den	
Berg	 and	 Miossec	 2009,	 Mieliauskaite,	 Dumalakiene	 et	 al.	 2012,	 Pollinger	 2012).	
Similar	to	IL-17,	IL-22	is	highly	expressed	by	Th17	cells	as	well,	studies	have	revealed	
that	IL-22	is	expressed	differentially	in	several	autoimmune	diseases	(Cheng,	Guo	et	
al.	2009,	Pan,	Zhao	et	al.	2009,	da	Rocha,	Duarte	et	al.	2012).	Mouse	models	showed	
that	 IL-22	knockout	or	 inhibition	might	ameliorate	some	autoimmune	diseases	(Ke,	
Sun	et	al.	2011,	Semerano,	Assier	et	al.	2012).	
	
1.2.7	IL-22	in	cancer	
On	the	one	hand,	IL-22	plays	a	protective	role	in	inflammation,	on	the	other	hand,	as	
a	double-edged	sword,	 IL-22	can	execute	an	 inflammatory	function	 in	autoimmune	
diseases,	 and	 moreover,	 promote	 tumor	 development	 by	 inducing	 inflammation,	
proliferation,	cell	migration,	angiogenesis	and	oxidative	signaling	via	STAT3	signaling	
(Lim	 and	 Savan	 2014).	 Aberrance	 of	 IL-22	 signaling	was	 shown	 to	 be	 important	 in	
various	cancers.	IL-22	was	shown	to	be	involved	in	cancer	signaling	in	several	sites,	
such	 as	 lung,	 pancreas,	 skin,	 colon,	 breast,	 stomach,	 thyroid,	 skin	 and	 cervix	
(Dudakov,	Hanash	et	al.	2015).	 	
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Studies	on	colon	cancer	and	hepatocellular	cancer	 indicated	that	excessive	 IL-22	 in	
the	 microenvironment	 of	 colon	 cancer,	 ulcerative	 colitis	 and	 hepatocellular	
carcinoma	 leads	 to	 tumor	 growth,	 apoptosis	 inhibition	 as	 well	 as	 metastasis	
promotion	 depend	 on	 STAT3	 activation	 (Jiang,	 Tan	 et	 al.	 2011,	 Jiang,	Wang	 et	 al.	
2013).	 In	 vitro,	 IL-22	 stimulation	 enhances	 the	 migration	 and	 invasion	 of	 gastric	
cancer	 cells	 by	 regulating	 IL-22RA1/AKT/MMP-9	 (matrix	 metalloproteinase	 9)	
signaling	 axis	 (Ji,	 Yang	 et	 al.	 2014).	 IL-22R	 is	 expressed	 on	 glioblastoma	 cells	
established	in	vivo	and	in	vitro,	and	IL-22	induced	glioblastoma	cell	survival	in	STAT3,	
ERK1/2	and	PI3K/Akt	pathways.	 In	gastric	 cancer,	 IL-22	 is	 important	 in	establishing	
the	tumor	microenvironment	and	increased	intratumoral	IL-22	correlates	with	tumor	
progression	 and	 predicts	 poor	 survival	 in	 patients	 (Zhuang,	 Peng	 et	 al.	 2012).	
Another	study	demonstrated	that	IL-22	levels	are	positively	associated	with	MAP3K8	
(mitogen-activated	 protein	 kinase	 kinase	 kinase	 8)	 and	 Pin1	 expression	 in	 breast	
cancer.	 IL-22-induced	 MAP3K8	 signaling	 pathway	 may	 promote	 cancer-associated	
inflammation	 in	 the	 tumor	 microenvironment	 (Kim,	 Kim	 et	 al.	 2014).	 In	 addition,	
IL-22	is	frequently	expressed	in	lung	cancer,	and	increased	IL-22RA1	expression	and	
signaling	 in	 chemotherapy	 refractory	 cell	 lines	 are	 indicative	 of	 a	 pro-tumorigenic	
function	 of	 IL-22	 and	 may	 contribute	 to	 a	 more	 aggressive	 phenotype.	 	
Overexpression	of	IL-22RA1	is	an	independent	indicator	of	poor	overall	survival	and	
supports	the	contribution	of	the	IL-22-IL-22RA1	pathway	in	lung	cancer	progression	
(Kobold,	Volk	et	al.	2013,	Guillon,	Gueugnon	et	al.	2016).	Moreover,	overall	survival	
of	patients	with	pancreatic	ductal	adenocarcinoma	was	 significantly	 shortershorter	
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in	 patients	 with	 high	 expression	 of	 IL-22	 and	 IL-22R	 than	 in	 those	 with	 low	
expression	 (Wen,	 Liao	 et	 al.	 2014).	One	 study	on	 IL-22	 and	 the	RCC	 cell	 line	A498	
showed	 that	 IL-22	 dose-dependently	 suppressed	 the	 growth	 of	 RCC	 A498	 cells	 by	
regulation	 of	 STAT1	 pathway	 (Zhang,	 Shang	 et	 al.	 2011).	 Despite	 the	 known	
correlation	 	 between	IL-22	and	different	types	of	cancers	from	previous	studies,	to	
our	 knowledge	 there	 is	 no	 published	 research	 on	 the	 relationship	 between	 the	
expression	of	IL-22/IL-22R1	and	survival	in	ccRCC	patients.	 	
	 	 	
1.3	Hypotheses	
Based	on	the	above,	we	therefore	hypothesized	that:	
1. Expression	of	IL-22-IL-22RA1	axis	proteins	is	correlated	with	ccRCC	patients’	
overall	survival	and	disease-free	survival.	To	this	end,	clinical	and	genomic	data	
of	ccRCC	provided	by	TCGA	were	analyzed	using	the	cBioPortal	resource.	
2. Expression	of	IL-22-IL-22RA1	axis	proteins	is	correlated	with	clinicopathological	
characteristics	of	ccRCC	patients.	To	verify	this	hypothesis,	we	quantified	the	
expression	of	IL-22	and	IL-22RA1	in	human	ccRCC	tissues	and	correlated	the	
expression	with	clinicopathological	characteristics	(age,	sex,	Fuhrman	grade,	
primary	T	stage,	present	of	necrosis,	venous	thrombus	and	relapse)	of	ccRCC	
patients.	
3. ccRCC	patients	with	lower	expression	level	of	IL-22,	IL-22RA1,	IL-22BP,	Ki-67,	
Caspase-3	have	a	longer	overall	survival	time	and	disease-free	survival	time.	We	
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assessed	the	expression	of	IL-22,	IL-22RA1,	and	IL-22BP,	Ki-67	and	Caspase-3	in	
human	ccRCC	tissues	and	correlated	the	expression	with	the	outcomes	of	ccRCC	
patients	in	our	patients’	cohort.	
4. IL-22RA1	and	IL-22	are	independent	predictive	factors	for	prognosis	of	ccRCC	
patients.	To	this	purpose,	a	multivariate	cox	proportional	hazards	model	was	
used	to	analyze	the	impact	of	prognostic	factors	on	overall	survival	and	
disease-free	survival.	
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2. Materials	and	Methods	
2.1	Materials	 	
100%	ethanol	 CLN,	Germany	
30%	hydrogen	peroxide	 Merck	KGaA,	Germany	
37$	 water	bath	 HAAKE,	Germany	
70%	ethanol	 CLN,	Germany	
96%	ethanol	 CLN,	Germany	
ABC	reagent	 Vector	Laboratories,	CA,	USA	
antigen	unmasking	solution	 Vector	Laboratories,	CA,	USA	
autoclave	 Melag,	Germany	
avidin	blocking	solution	 Vector	Laboratories,	CA,	USA	
biotin	blocking	solution	 Vector	Laboratories,	CA,	USA	
biotinylated	anti-goat	antibody	 BA-9500,	Vector	Laboratories,	CA,	USA	
biotinylated	anti-mouse	IgG1	antibody	 406604,	BioLegend,	CA,	USA	
biotinylated	anti-rabbit	antibody	 BA1000,	Vector	Laboratories,	CA,	USA	
cleaved	caspase-3	antibody	 9661S,	Cell	Signaling,	MA,	USA	
cover	slips	 VWR,	Pennsylvania,	USA	
DAB	 Sigma-Aldrich,	Mo.	USA	
distilled	water	 made	in	our	lab	
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drying	oven	 Memmert,	Germany	
goat	serum	 Thermo	Scientific,	USA	
GraphPad	Prism	 GraphPad	Prism	6.0	
IBM	SPSS	 	 IBM	SPSS	22	
IL-22	antibody	 sc-14436,	Santa	Cruz	Biotech,	Texas,	USA	
IL-22BP	antibody	 NBP1-85455,	Novus	Biologicals,	CO,	USA	
IL-22RA1	antibody	 ab5984,	Abcam,	UK	
Image	J	 National	Institutes	of	Health	
Ki-67	antibody	 BD	550609,	BD	Biosciences,	CA,	USA	
methanol	 Sigma-Aldrich,	Mo.	USA	
methyl	green	 Sigma-Aldrich,	Mo.	USA	
microscope	 	 Leica	Microsystems,	Germany	
microscope	slides	 Thermo	Scientific,	USA	
microtome	 	 Thermo	Scientific	Microm	HM355S,	USA	
Microwave	 Severin,	Germany	
mounting	medium	 Vector	Laboratories,	CA,	USA	
NiCl	 Sigma-Aldrich,	Mo.	USA	
PBS	 PAN-Biotech,	Germany	
proteinase	K	 Qiagen,	Germany	
Tris-Hcl	 made	in	our	lab	
Windows	system	 Microsoft	Windows	7	
xylene	 Fisher	Scientific,	UK	
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2.2	The	cancer	genome	atlas	data	analysis	 	
The	 cancer	 genome	atlas	 (TCGA)	 is	 a	 cooperation	program	by	 the	National	Cancer	
Institute	 (NCI)	 and	 National	 Human	 Genome	 Research	 Institute	 (NHGRI),	 it	 has	
synthetic	 multi-dimensional	 maps	 of	 the	 pivotal	 genomic	 changes	 as	 well	 as	
molecular	 and	 clinical	 data	 in	 33	 types	 of	 cancer	 so	 far	
(http://cancergenome.nih.gov/).	 The	 principal	 objectives	 of	 TCGA	 are	 vigorous	
quality	 control	 as	 well	 as	 to	 generate,	 ,	 merge,	 analyze,	 and	 clarify	 molecular	
characteristics	 at	 the	 DNA,	 RNA,	 protein	 and	 epigenetic	 levels	 for	 hundreds	 of	
cancers	 from	 various	 tumor	 types	 and	 subtypes	 (Cancer	 Genome	 Atlas	 Research,	
Weinstein	 et	 al.	 2013).	 Researchers	 can	 collect,	 select,	 and	 analyze	 human	 tumor	
tissues	 of	 the	 genomic	 database	 established	 by	 TCGA	 and	 this	 national	 network	
serves	 as	 a	model	 for	 projects	 in	 the	 future.	 Tumors	profiled	by	 TCGA	 range	 from	
solid	 to	hematological,	 from	moderate	 to	highly	malignant.	DNA,	RNA	and	protein	
are	 extracted	 and	 analyzed	 for	 each	 tumor	 case.	 	 TCGA	 collects	 and	 analyzes	
high-quality	tumor	tissues	and	makes	these	following	data	usable	on	the	TCGA	Data	
Portal:	
1) Clinical	information	about	participants	in	the	program	
2) Metadata	about	the	samples	
3) Histopathology	slides	images	from	sample	portions	
4) Molecular	information	derived	from	the	samples	(e.g.	mRNA/miRNA	expression,	
protein	 expression,	 copy	 number,	 etc.)	 (NCI	 Wiki	
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https://wiki.nci.nih.gov/display/TCGA/About+TCGA+Data)	
Pan-cancer	 is	 a	 coordinated	 initiative,	 its	 aim	 being	 the	 assemlyof	 coherent,	
consistent	 data	 sets	 from	TCGA	and	 separate	 disease	 projects,	 then	 analyzing	 and	
interpreting	 these	 data	 to	 build	 a	 well-coordinated	 joint	 data	 set	 sweeping	 into	
multiple	 tumor	 types	 (Cancer	Genome	Atlas	 Research,	Weinstein	 et	 al.	 2013).	 The	
Pan-Cancer	analysis	program	was	established	as	a	collaboration	among	members	of	
the	TCGA	network,	however,	many	other	interested	institutions	were	involved	soon	
after	starting.	 	
	
The	 findings	 from	TCGA	have	provided	a	 large	amount	of	 advanced	knowledge	on	
the	cancers	and	therefore	have	given	rise	to	the	development	of	clinical	diagnostic	
and	prognostic	biomarkers	even	redefinitions	of	preceding	classifications	of	cancers	
(Colaprico,	 Silva	 et	 al.	 2016).	 	 However,	 it	 is	 not	 easy	 for	 cancer	 researchers	 to	
translate	 the	 genomic	 data	 from	 this	 kind	 of	 large-scale	 cancer	 genomics	 projects	
into	new	biologic	insights	and	clinical	applications.	 	
	
cBioPortal	 (http://www.cbioportal.org/)	 is	 an	 open-access	 resource	 for	 Cancer	
Genomics	 which	 provides	 visualization,	 analysis	 and	 download	 options	 of	
multidimensional	cancer	genomics	data	sets	and	makes	the	raw	data	generated	by	
large-scale	 cancer	 genomics	 projects	 such	 as	 TCGA	 and	 ICGC	 (the	 International	
Cancer	Genome	Consortium)	more	easily	and	directly	available	 (Cerami,	Gao	et	al.	
2012).	 cBioPortal	 enables	 researchers	 to	 explore	 genetic	 alterations	 and	 gene	
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expression	interactively	across	different	tissues	and	to	link	these	underlying	data	to	
clinical	outcomes	(Gao,	Aksoy	et	al.	2013).	 	
	
In	a	single-cancer	query,	researchers	can	select	cancer	need	to	study,	select	genomic	
profiles	and	enter	gene	name.	As	shown	in	Figure	3,	kidney	renal	clear	cell	carcinoma	
(TCGA,	provisional)	which	includes	538	samples	was	selected	for	the	present	study.	
	
	
Figure	3	Select	genomic	profiles.	 	
	
The	next	step	was	to	select	genomic	profiles.	We	selected	mRNA	Expression	z-Scores	
(RNA	Seq	V2	RSEM)	which	meant	compared	 to	 the	expression	distribution	of	each	
gene	tumors	that	were	diploid	for	this	gene,	and	then	entered	a	z-score	threshold.	A	
z-score	 is	 also	 known	 as	 a	 standard	 score,	 is	 a	 measure	 of	 how	 many	 standard	
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deviations	 below	or	 above	 the	 population	mean	 a	 raw	 score	 is.	 z	 =	 (expression	 in	
tumor	 sample	 –	 mean	 expression	 in	 reference	 sample)	 /	 standard	 deviation	 of	
expression	in	reference	sample.	(Figure	4)	
	
	
Figure	4	Select	genomic	profiles.	 	
	
After	that,	“All	Complete	Tumors”	was	selected	from	the	list.	Then	gene	symbol	was	
typed	in	the	blank	before	submitting,	as	shown	in	Figure	5.	
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Figure	5	Select	patient	or	case	set,	enter	gene	symbol.	
	
Comprehensive	results	were	come	out	after	submitting.	As	shown	in	Figure	6,	35	(8%)	
of	 413	 cases	exist	 IL-22	mRNA	upregulation.	Meanwhile,	 several	 different	 types	of	
data	were	also	shown	here,	such	as	mutual	exclusivity,	plots,	mutations	and	so	on.	 	
	
	
Figure	6	Comprehensive	results	were	shown	after	submitting.	 	
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2.3	Patients	and	samples	
60	 cases	 tumor	 samples	 from	 non-metastatic	 ccRCC	 patients	 from	 Department	 of	
Urology,	Hospital	of	the	Ludwig-Maximilians-University	Munich	were	included	in	the	
study.	 All	 patients	 were	 treated	 with	 radical	 or	 partial	 nephrectomy	 between	
December	 1991	 and	 July	 2004.	 Diagnosis	 of	 ccRCC	was	 confirmed	 by	 hematoxylin	
and	 eosin	 (H&E)	 staining	 by	 the	 Department	 of	 Pathology	 of	 the	 Hospital	 of	 the	
Ludwig-Maximilians-University	 Munich.	 Written,	 informed	 consent	 was	 obtained	
from	 all	 patients	 before	 surgery,	 and	 the	 study	 was	 approved	 by	 the	 Ethics	
Committee	of	the	Hospital	of	the	Ludwig-Maximilians-University	Munich.	Complete	
follow-up	 history	 was	 available	 for	 at	 least	 5	 years.	 Clinical	 and	 pathological	
parameters	 were	 entered	 into	 a	 database,	 included	 age,	 sex,	 Fuhrman	 grade,	
primary	 T	 stage,	 present	 of	 necrosis,	 venous	 thrombus	 and	 relapse.	 Cases	 in	 this	
study	 were	 re-assigned	 according	 to	 the	 2010	 AJCC	 TNM	 classification	 (Edge	 and	
Compton	2010)(Table	1).	All	 the	stages	were	classified	 into	 two	groups,	high	stage	
(T3	 and	 T4)	 and	 low	 stage	 (T1	 and	 T2).	 All	 the	 tumor	 samples	were	 embedded	 in	
paraffin	 after	 surgery,	 together	 with	 adjacent	 non-tumor	 tissue	 from	 the	 same	
patient.	µ4µm-thick	sections	from	tumor	blocks	were	cut	by	microtome	and	allowed	
to	 air-dry	 overnight	 for	 the	 immunohistochemistry	 staining.	 Patients’	 clinical	 data	
are	shown	in	Table	3.	
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Table	1	2010	AJCC	TNM	classification	(Primary	tumors	stage)	
Primary	tumors	(T)	
TX	 Primary	tumor	cannot	be	assessed	
T0	 No	evidence	of	primary	tumor	
T1	 Tumor	≤7	cm	in	greatest	dimension,	limited	to	the	kidney	
T1a	 Tumor	≤4	cm	in	greatest	dimension,	limited	to	the	kidney	
T1b	 Tumor	>4	cm	but	≤7	cm	in	greatest	dimension,	limited	to	the	kidney	
T2	 Tumor	>7	cm	in	greatest	dimension,	limited	to	the	kidney	
T2a	 Tumor	>7	cm	but	≤10	cm	in	greatest	dimension,	limited	to	the	kidney	
T2b	 Tumor	>10	cm,	limited	to	the	kidney	
T3	 Tumor	 extends	 into	 major	 veins	 or	 perinephric	 tissues	 but	 not	 into	 the	
ipsilateral	adrenal	gland	and	not	beyond	the	Gerota	fascia	
T3a	 Tumor	 grossly	 extends	 into	 the	 renal	 vein	 or	 its	 segmental	
(muscle-containing)	branches,	or	tumor	invades	perirenal	and/or	renal	sinus	
fat	but	not	beyond	the	Gerota	fascia	
T3b	 Tumor	grossly	extends	into	the	vena	cava	below	the	diaphragm	
T3c	 Tumor	grossly	extends	 into	 the	vena	cava	above	the	diaphragm	or	 invades	
the	wall	of	the	vena	cava	
T4	 Tumor	 invades	 beyond	 the	 Gerota	 fascia	 (including	 contiguous	 extension	
into	the	ipsilateral	adrenal	gland)	
	
2.4	Immunohistochemistry	
Immunohistochemistry	 staining	 for	 IL-22,	 IL-22	 receptor	 (IL-22RA1),	 IL-22	 binding	
protein	 (IL-22BP),	 ki-67	 and	 caspase-3	 was	 performed	 as	 follows.	 Appropriate	
positive	and	negative	controls	were	utilized	 for	each	run	of	 immunohistochemistry	
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staining.	 	
	
First,	 tissue	 slides	 were	 deparaffinizedn.	 For	 this,	 sections	 were	 incubated	 in	 two	
washes	 of	 xylene	 for	 5	 minutes	 each	 at	 room	 temperature.	 Then	 slides	 were	
incubated	 in	 three	washes	 of	 100%	 ethanol,	 two	washes	 of	 96%	 ethanol	 and	 one	
wash	of	70%	ethanol	for	2	minutes	each	at	room	temperature,	followed	by	washing	
sections	 twice	 in	 phosphate	 buffered	 saline	 (PBS)	 for	 7	 minutes	 each	 at	 room	
temperature.	 	
	
The	second	step	was	endogenous	peroxidase	blocking.	Sections	were	incubated	in	3%	
hydrogen	peroxide	(20ml	30%	hydrogen	peroxide	in	180ml	methanol)	for	20	minutes	
in	dark	at	room	temperature,	followed	by	washing	sections	in	PBS	for	7	minutes	at	
room	temperature.	 	
	
The	 third	 step	 was	 antigen	 unmasking.Slides	 were	 boiled	 (Microwave)	 in	 10	 mM	
sodium	 citrate	 buffer	 (pH	 6.0):	 300ml	 distilled	 water	 +	 3ml	 antigen	 unmasking	
solution	and	then	cooled	on	bench	top	for	30	minutes.	Then	slides	were	autoclaved	
with	 sodium	 citrate	 buffer	 for	 20	 minutes	 followed	 by	 40	 minutes	 cooling	 down.	
Sections	 were	 washed	 in	 PBS	 for	 7	 minutes	 at	 room	 temperature.	 For	 IL-22	 and	
IL-22RA1	 staining,	 proteinase	 K	 solution	 (1:400)	 was	 used	 for	 antigen	 unmasking	
instead	of	sodium	citrate	buffer.	Added	µ200µl	proteinase	K	solution	(1:400)	to	each	
section,	incubated	for	10	minutes	at	room	temperature,	and	then	washed	in	PBS	for	
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7	minutes	at	room	temperature.	 	
The	 next	 step	 was	 antigen	 detection.	 Each	 section	 was	 first	 blocked	 with	 several	
drops	 of	 avidin	 blocking	 solution	 for	 15	 minutes	 at	 room	 temperature,	 and	 then	
washed	 briefly	 in	 PBS.	 Sections	 were	 then	 blocked	 with	 several	 drops	 of	 biotin	
blocking	solution	for	15	minutes	at	room	temperature,	followed	by	washing	sections	
in	 PBS	 for	 7	 minutes.	 Before	 antibody	 incubation,	 tissue	 sections	 were	 incubated	
with	 10%	 normal	 goat	 serum	 for	 10	 minutes	 at	 room	 temperature	 to	 block	
non-specific	binding	from	the	goat	second	antibody.	 	
	
Primary	 and	 second	 antibody	 incubation	 was	 performed	 at	 this	 step.	 Antibody	
dilutionsare	shown	in	table	2.	µ200	µl	of	the	diluted	primary	antibody	solution	were	
added	to	each	section	and	incubated	for	1	hour	at	room	temperature	or	overnight	at	
4℃	 and	 	 sections	were	washed	twice	in	PBS	for	7	minutes	after	incubation.	200µl	
biotinylated	diluted	second	antibody	solution	were	then	added	to	each	section	and	
incubated	for	30	minutes	at	room	temperature	followed	by	washing	twice	in	PBS	for	
7	minutes.	 	
	
The	next	step	was	ABC	reagent	incubation.	ABC	solution	preparation:	15µl	reagent	A	
and	15µl	reagent	B	to	1	ml	PBS.	200µl	ABC	solution	was	added	to	each	section	and	
then	incubated	for	30	minutes	at	room	temperature	and	then	sections	were	washed	
twice	in	PBS	for	5	minutes	followed	by	washing	in	Tris-Hcl	buffer	(pH	7.6-7.8)	twice	
for	5	minutes.	
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The	last	step	was	staining.	Staining	solution	(37$)	preparation:	200	ml	Tris-Hcl	+	4ml	
DAB	 (3,3'-diaminobenzidine)	 solution	+	1ml	NiCl	 (Nickel	 chloride)	 +	 500µl	 3%	H2O2	
(hydrogen	peroxide).	At	first	sections	were	incubated	in	staining	solution	for	2	to	10	
minutes	 at	 37$.	 The	 slides	 were	 then	 counterstained	 with	 methyl	 green	 for	 2	
minutes	at	room	temperature.	Then	slides	were	incubated	in	three	washes	of	100%	
ethanol,	 two	washes	of	96%	ethanol	and	one	wash	of	70%	ethanol	 for	10	seconds	
each	 at	 room	 temperature,	 followed	by	 incubating	 sections	 twice	 in	 xylene	 for	 10	
seconds	 each	 at	 room	 temperature,	 and	 then	 mounted	 coverslips	 with	 mounting	
medium.	Images	were	captured	with	a	LEICA	AMIL	instrument.	 	
	
Table	2	Primary	and	second	antibodies	
Primary	antibody	 dilution	 incubate	time	 second	antibody	
IL-22	 	 1:100	 1	hour	 anti-goat	antibody	
IL-22RA1	 1:200	 1	hour	 anti-rabbit	antibody	
IL-22BP	 1:100	 overnight	 anti-rabbit	antibody	
Ki-67	 1:50	 1	hour	 anti-mouse	antibody	
Caspase-3	 1:50	 overnight	 anti-rabbit	antibody	
	
2.5	Staining	Evaluation	
2.5.1	IL-22	and	IL-22BP	staining	evaluation	
5	 representative	 areas	 (X	 100)	 from	 the	 entire	 slides	 were	 selected	 under	 the	
microscope.	 Positive	 signals	 were	 counted	 in	 all	 the	 5	 areas.	 The	 observer	 was	
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blinded	 to	 the	 outcome	 or	 characteristics	 of	 the	 patient	 when	 evaluating	 the	
staining.	
	
2.5.2	IL-22RA1	staining	evaluation	
5	 representative	 areas	 (X	 100)	 from	 the	 tumor	 tissue	 as	 well	 as	 one	 area	 from	
adjacent	non-tumor	tissue	were	selected	under	microscope.	Pictures	of	these	areas	
were	 analyzed	 via	 Image	 J	 software	 as	 following:	 Opened	 the	 picture	 of	 adjacent	
non-tumor	tissue	in	Image	J,	then	selected	‘Image’	from	the	main	menu	of	 Image	J	
% 	 Color	 % 	 Split	 Channels,	 the	 picture	 was	 split	 into	 three	 different	
channels—blue,	green	and	red.	Kept	 the	green	one,	and	selected	 ‘Image’	 from	the	
main	menu	of	Image	J	 %	 Adjust	 %	 Threshold,	then	adjusted	the	parameters	until	
all	 the	 background	 was	 removed	 and	 positive	 signals	 were	 shown	 in	 the	 picture.	
Recorded	the	parameters	and	clicked	‘Apply’,	then	selected	‘Analyze’	from	the	main	
menu	 %	 Measure,	 then	 the	 staining	 value	 was	 calculated	 automatically.	 Same	
processing	for	pictures	of	tumor	tissues	was	performed	under	the	same	parameters,	
in	 this	 way,	 the	 staining	 values	 could	 be	 compared	 between	 adjacent	 non-tumor	
tissue	 and	 tumor	 tissues	 from	 the	 same	 case,	 as	 well	 as	 normalised	 the	 tumor	
staining	values	by	adjacent	non-tumor	staining	values.	The	observer	was	blinded	to	
the	outcome	or	characteristics	of	the	patient	when	evaluating	the	staining.	 	
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2.5.3	Ki-67	and	Caspase-3	staining	evaluation	
A	 semiquantitative	 scoring	 method	 was	 used	 to	 evaluate	 ki-67	 and	 caspase-3	
staining.	 Both	 the	 staining	 intensity	 and	 the	 proportion	 of	 cells	 stained	 were	
assessed	(Zhu,	Cai	et	al.	2012).	The	total	 immunostaining	scores	were	calculated	as	
the	intensity	score	(0=	no	staining,	1=weak	staining,	2=moderate	staining,	3=strong	
staining)	 #	 the	proportion	of	positively	stained	cells	(0	to	100%)	The	observer	was	
blinded	 to	 the	 outcome	 or	 characteristics	 of	 the	 patient	 when	 evaluating	 the	
staining.	
	
2.6	Statistical	Analysis	
Correlations	 between	 immunohistochemical	 variables	 and	 clinicopathological	
characteristics	were	analyzed	by	Fisher	exact	and	chi-square	tests.	According	to	the	
NCI	definition,	overall	survival	(OS)	refers	to	the	length	of	time	from	either	the	date	
of	 diagnosis	 or	 the	 start	 of	 treatment	 for	 a	 disease,	 such	 as	 cancer,	 that	 patients	
diagnosed	with	the	disease	are	still	alive.	Disease-free	survival	(DFS)	was	considered	
as	 the	 length	 of	 time	 after	 primary	 treatment	 for	 cancer	 ends	 that	 the	 patient	
survives	without	any	signs	or	symptoms	of	that	cancer.	Depending	on	this,	death	and	
relapse	 were	 selected	 as	 two	 different	 end	 points	 during	 follow-up	 period	 to	
perform	 the	 Kaplan-Meier	 analyses,	 with	 log-rank	 tests	 assessing	 the	 differences	
between	 the	 groups.	 Multivariate	 Cox	 proportional	 hazards	 models	 were	 used	 to	
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analyze	the	impact	of	prognostic	factors	on	overall	survival	and	disease-free	survival.	
All	 statistical	 tests	 were	 performed	 assuming	 significance	 at	 a	 level	 of	 p<0.05.	
Analyzes	 were	 performed	 using	 GraphPad	 Prism,	 version	 5.04	 and	 IBM	 SPSS	
Statistics,	version22.	
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3. Results	
3.1	 Correlations	 between	 IL-22	 and	 ccRCC	 patients’	 overall	
survival	 and	 disease-free	 survival	 from	 the	 cancer	 genome	
atlas	
Initially	 the	 correlation	 between	 levels	 of	 IL-22	 and	 ccRCC	 patients’	 survival	 from	
TCGA	was	analyzed.	There	were	35	cases	(8%)	with	upregulation	of	IL-22	and	other	
378	cases	(92%)	without	upregulation	of	IL-22,	and	the	cases	deceased	were	18	and	
127,	respectively.	Median	survival	was	62.81	and	90.8	months,	respectively.	Log-rank	
test	 showed	 p-value=0.0159,	 patients	 with	 IL-22	 overexpression	 shorterlinked	 to	
shorter	overall	survival	compared	to	cases	without	upregulation	of	IL-22.	(Figure	7A)	
Similarly,	 in	 the	 disease-free	 survival	 Kaplan-Meier	 estimate,	 there	 were	 28	 cases	
(8%)	with	high	level	of	IL-22	and	307	patients	(92%)	with	low	level	of	IL-22,	the	cases	
relapsed	 during	 the	 follow-up	 period	 were	 14	 and	 94,	 respectively.	 Median	
disease-free	 survival	 was	 32.52	 and	 123.72	 months.	 Log-rank	 test	 showed	
p-value=0.0047,	 patients	 with	 upregulation	 of	 IL-22	 had	 a	 shorter	 disease	 free	
survival	compared	to	patients	without	this	alteration	in	IL-22.	(Figure	7B)	
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Figure	 7	 IL-22	 Kaplan-Meier	 survival	 estimates.	 A	 Patients	without	 IL-22	upregulation	have	 a	
better	overall	survival.	B	Patients	without	IL-22	upregulation	have	a	better	disease-free	survival.	
	
A	
B	 	 	 	
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3.2	Correlations	between	IL-22RA1	and	ccRCC	patients’	overall	
survival	 and	 disease-free	 survival	 from	 the	 cancer	 genome	
atlas	
Regarding	IL-22RA1,	the	number	of	patients	with	and	without	IL-22RA1	was	33	(8%)	
and	380	(92%).	20	of	the	33	cases	died	during	the	follow-up	period,	and	125	of	the	
380	cases	died	during	this	period.	Median	survival	time	was	45.27	months	and	90.8	
months,	respectively.	P-value=0.0013,	which	meant	the	overall	survival	was	better	in	
patients	with	low	level	of	IL-22RA1	than	patients	with	high	level	of	IL-22RA1	(Figure	
8A).	Disease-free	survival	analysis	 is	 shown	 in	Figure	8B.	There	were	23	cases	 (7%)	
with	 upregulation	 of	 IL-22RA1	 and	 312	 cases	 (93%)	without	 alteration,	 during	 the	
follow-up	 period,	 there	 were	 12	 cases	 and	 96	 cases	 relapsed,	 respectively.	
Meanwhile,	 the	 median	 disease-free	 time	 was	 56.14	 months	 and	 123.72	 months	
respectively.	 P-Value	 from	 the	 log-rank	 test	 was	 0.0404,	 manifested	 a	 better	
disease-free	survival	in	cases	with	low	level	of	IL-22RA1,	compared	to	patients	with	
IL-22RA1	upregulation.	 	 	
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Figure	 8	 IL-22RA1	 Kaplan-Meier	 survival	 estimates.	 A	 Patients	 without	 IL-22RA1	
upregulation	have	a	better	overall	survival.	B	Patients	without	IL-22RA1	upregulation	have	a	
better	disease-free	survival.	
	
A	
B	
41	
Results	
3.3	Clinical	data	of	patient	cohort	of	Munich	 	
As	listed	in	Table	4,	among	the	60	patients	with	ccRCC,	30	were	female	(50%),	and	30	
were	male	(50%),	age	ranged	from	31	years	to	77	years,	the	mean	age	was	59	years,	
among	 them,	 27	 (45%)	 patients	 aged	 less	 than	 or	 equal	 to	 60	 years,	 33	 (55%)	
patients	 aged	 more	 than	 60	 years.	 Fuhrman	 grades	 were	 estimated	 by	 the	
department	 of	 pathology	 using	 the	 Fuhrman	 grading	 system,	 among	 these	 60	
patients,	46	cases	were	in	low	Fuhrman	grade	(G1	or	G2)	(76.7%),	and	14	cases	were	
in	 high	 Fuhrman	 grade	 (G3	 or	 G4)	 (23.3%).	 Pathological	 stages	 were	 re-assigned	
according	 to	 the	 2010	 American	 Joint	 Committee	 on	 Cancer	 (AJCC)	 TNM	
classification.	The	primary	T	 stages	were	 low	 (T1	or	T2)	 in	46	patients	 (76.7%)	and	
high	(T3	or	T4)	in	14	patients	(23.3%).	 	 The	existence	of	tumor	necrosis	was	judged	
by	conventional	hematoxylin	and	eosin	staining	by	pathologists.	Tumor	necrosis	was	
presented	 in	 16	 cases	 (26.7%)	 and	 absent	 in	 44	 cases	 (73.3%).	 The	 presence	 of	
venous	 thrombus	 was	 determined	 by	 imaging	 examination	 such	 as	 computerised	
tomography	 (CT)	 scan,	 Magnetic	 Resonance	 Imaging	 (MRI)	 and	 ultrasonic	
examination,	 as	 well	 as	 venous	 thrombus	 observation	 during	 or	 after	 surgery.	
Venous	 thrombus	 was	 presented	 in	 8	 patients	 (13.3%)	 and	 absent	 in	 52	 patients	
(86.7%).	 	
	
During	the	follow-up	period,	18	patients	(30%)	had	disease	recurrence	and	a	total	of	
23	patients	(38.3%)	died	due	to	all	causes.	The	presence	of	relapse	was	assessed	by	
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imaging	 examination	 and	 pathological	 examination	 during	 the	 follow-up	 period.	
Relapses	 included	 local	kidney	tumor	recurrence	 in	the	original	 location,	a	regional	
recurrence	that	occurred	in	the	lymph	nodes	as	well	as	metastasis	in	other	parts	of	
the	body	or	organs.	In	these	60	cases,	18	patients	had	disease	recurrence,	including	
local	recurrence	in	5	patients,	lymph	nodes	recurrence	in	2	cases,	bone	metastasis	in	
7	cases,	brain	metastasis	in	3	patients,	liver	metastasis	in	2	patients,	lung	metastasis	
in	8	cased	and	skin	metastasis	in	one	patient.	As	more	than	one	recurrence	site	was	
found	 in	 some	 patients,	 the	 number	 of	 recurrence	 sites	 is	 shown	 in	 Table	 3.	 The	
follow-up	period	ranged	from	13	months	to	182	months,	and	the	median	follow-up	
time	was	78	months	for	the	cohort.	
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Table	3	Patients’	clinical	data.	
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1 50 0 1 T1A 0 0 0 0 106 
2 37 0 1 T1B 3 0 0 0 175 
3 63 1 1 T1B 1 0 0 0 143 
4 66 1 1 T1B 0 0 0 0 48 
5 74 1 1 T1B 0 0 0 0 75 
6 65 1 1 T2B 0 0 0 0 178 
7 49 1 1 T3A 1 0 0 0 179 
8 68 0 2 T1A 0 0 0 0 22 
9 73 0 2 T1A 0 0 0 0 54 
10 34 1 2 T1A 0 0 0 0 129 
11 47 1 2 T1A 1 0 0 0 182 
12 55 1 2 T1A 0 0 0 0 105 
13 58 1 2 T1A 0 0 0 0 132 
14 62 1 2 T1A 0 0 0 0 145 
15 65 1 2 T1A 0 0 0 0 172 
16 66 1 2 T1A 1 0 0 0 182 
17 31 0 2 T2A 1 0 0 0 124 
18 34 0 2 T2A 0 0 0 0 13
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19 49 0 2 T2A 3 0 0 0 142 
20 49 0 2 T2A 0 0 0 0 26 
21 51 0 2 T2A 0 0 0 0 100 
22 55 0 2 T2A 0 0 0 0 106 
23 64 0 2 T2A 0 0 0 0 86 
24 65 0 2 T2A 0 0 0 0 148 
25 68 0 2 T2A 0 0 0 0 98 
26 62 1 2 T2A 0 0 0 0 26 
27 75 1 2 T2A 0 0 0 0 122 
28 52 0 2 T2B 0 0 0 0 78 
29 67 0 2 T2B 0 0 0 0 70 
30 72 0 2 T2B 0 0 0 0 89 
31 36 1 2 T2B 0 0 0 0 77 
32 73 1 2 T2B 0 0 0 0 42 
33 71 0 1 T1A 0 0 0 1 80 
34 41 1 1 T1A 0 0 0 1 143 
35 77 1 1 T1B 0 0 0 1 54 
36 69 1 1 T2A 0 0 0 1 88 
37 45 0 2 T2A 0 0 0 1 52
38 66 0 2 T2A 0 0 0 1 42 
39 75 0 2 T2A 0 0 0 1 75 
40 76 0 2 T2A 0 0 0 1 51 
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41 57 1 3 T3B 3 1 0 1 74 
42 60 1 3 T3B 3 2 0 1 36 
43 53 1 2 T3B 0 2 1 1 54 
44 58 1 2 T2A 0 0 2 0 111 
45 63 1 3 T1A 0 0 2 0 96 
46 50 0 3 T2A 0 0 2 0 58 
47 65 0 2 T3B 1 1 2 0 13 
48 76 1 2 T3B 0 1 2 0 24 
49 38 0 2 T3A 2 0 2 1 39 
50 57 0 3 T1B 0 0 2 1 60 
51 62 0 3 T2A 0 0 2 1 31 
52 58 1 3 T2A 1 0 2 1 151 
53 62 0 3 T3B 0 1 2 1 52 
54 69 0 3 T3B 1 1 2 1 38 
55 61 1 3 T3B 3 1 2 1 124 
56 66 1 2 T3A 0 0 3 1 37
57 72 1 3 T1B 0 0 3 1 36 
58 59 1 3 T3A 0 0 3 1 57 
59 44 0 4 T4 1 0 3 1 26 
60 62 0 3 T4 3 0 3 1 80 
Sex:	0=female;	1=male.	Vital	status:	0=alive;	1=dead	
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Table	4	Patients’	cohort.	 	
	
NO	(60)	 %	
Age	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 <=60	 27	 45	
>60	 33	 55	
Sex	
	 	Male	 30	 50	
Female	 30	 50	
Fuhrman	grade	
	 	Low(G1/G2)	 46	 76.7	
High(G3/G4)	 14	 23.3	
Primary	T	stage	
	 	Low(pT1/pT2)	 46	 76.7	
High(pT3/pT4)	 14	 23.3	
Necrosis	
	 	Absent	 44	 73.3	
Present	 16	 26.7	
Venous	thrombus	
	 	Absent	 52	 86.7	
Present	 8	 13.3	
Relapse	
	 	Absent	 42	 70	
Present	 18	 30	
Vital	status	
	 	Alive	 37	 61.7	
Dead	 23	 38.3	
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3.4	Immunohistochemical	detection	of	IL-22,	IL-22RA1	IL-22BP,	
Ki-67	and	caspase-3	
IL-22	 staining	was	present	predominantly	 in	 the	 cytoplasm.	The	 staining	pattern	 is	
shown	in	Figure	9.	There	is	only	a	little	expression	in	adjacent	normal	kidney	tissue.	
High	expression	of	IL-22	was	identified	as	equal	or	more	than	20	positive	signals	in	all	
5	areas	randomly	selected	under	microscope,	low	expression	of	IL-22	was	identified	
as	 less	 than	20	positive	 signals	 or	 negative	 result,	 the	number	of	 cases	 expressing	
high	and	low	IL-22	was	28	(46.7%)	and	32	(53.3%),	respectively.	 	
	
	
	
Figure	 9	 IL-22	 immunohistochemical	
staining.	A	Adjacent	normal	kidney	tissue;	
B	 Low	 expression	 of	 IL-22;	 C	 High	
expression	of	IL-22.	(X	100)	
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Similarly,	IL-22RA1	staining	was	present	in	the	cytoplasm	of	tumor	cells,	as	shown	in	
Figure	 10.	 There	 is	 a	moderate	 expression	 of	 IL-22RA1	 in	 adjacent	 normal	 kidney	
tissue.	 High	 expression	 of	 IL-22RA1	 was	 defined	 as	 equal	 or	 more	 than	 20	 score	
measured	by	 Image	 J	 software	mentioned	before;	 low	expression	of	 IL-22RA1	was	
defined	 as	 less	 than	 20	 score.	 The	 number	 of	 cases	with	 high	 expression	 and	 low	
expression	of	IL-22RA1	was	34	(56.7%)	and	26	(43.3%),	respectively.	 	
	
IL-22BP	 staining	 was	 only	 found	 in	 adjacent	 normal	 kidney	 tissue	 with	 moderate	
cytoplasmic	staining	and	luminal	membrane	positivity	in	tubules.	Positive	staining	for	
IL-22BP	in	tumor	tissue	slides	was	not	detected,	as	shown	in	Figure	11.	
	
	
Figure	 10	 IL-22RA1	 immunohistochemical	
staining.	 	 A	Adjacent	normal	kidney	tissue;	
B	 Low	 expression	 of	 IL-22RA1;	 C	 High	
expression	of	IL-22RA1.	(X	100)	
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Figure	 11	 IL-22BP	 immunohistochemical	 staining.	 	 A	 Adjacent	 normal	 kidney	 tissue;	 B	
ccRCC	tumor	tissue.	(X	100)	
	
Ki-67	staining	is	shown	in	Figure	12.	Very	few	positive	cells	can	be	seen	in	adjacent	
normal	 kidney	 tissue.	 Depending	 on	 the	 results,	 High	 expression	 of	 Ki-67	 was	
identified	as	equal	or	more	than	30	score	(mean	value),	low	expression	of	Ki-67	was	
identified	as	less	than	30	score	or	negative	result.	
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Caspase-3	 staining	 is	 shown	 in	 Figure	 13.	 Several	 cells	 were	 stained	 in	 adjacent	
normal	 kidney	 tissue.	 Depending	 on	 the	 staining	 evaluation	 results,	 High	 level	 of	
caspase-3	was	also	identified	as	equal	or	more	than	30	score	(mean	value),	low	level	
of	caspase-3	was	identified	as	less	than	30	score	or	negative	result.	
	
Figure	 12	 Ki-67	 immunohistochemical	
staining.	A	Adjacent	normal	kidney	tissue;	
B	 Low	 expression	 of	 ki-67;	 C	 High	
expression	of	ki-67.	(X	100)	
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3.5	Correlations	between	IL-22	expression	and	ccRCC	patients’	
clinicopathologic	characteristics	
As	listed	in	Table	5,	in	the	group	which	patients	aged	equal	or	less	than	60	years	old,	
there	 were	 15	 cases	 and	 12	 cases	 with	 high	 IL-22	 expression	 and	 low	 IL-22	
expression,	respectively.	While	in	the	group	aged	more	than	60	years	old,	the	cases	
expressing	high	level	and	low	level	of	IL-22	were	13	and	20,	respectively.	There	was	
no	significant	difference	in	IL-22	expression	between	two	groups.	(p=0.2988)	
	
In	 terms	of	gender,	 in	male	patients,	 there	were	14	cases	and	16	cases	expressing	
Figure	 13	 Caspase-3	 immunohistochemical	
staining.	 A	 Adjacent	 normal	 kidney	 tissue;	 B	
Low	 expression	 of	 caspase-3;	 C	 High	
expression	of	caspase-3.	(	X	100)	
	
52	
Results	
high	and	low	levels	of	IL-22.	Meanwhile	there	were	also	14	cases	and	16	cases	with	
high	and	 low	expression	of	 IL-22,	 respectively	 in	 female	patients.	This	meant	 there	
was	no	significance	of	IL-22	expression	between	genders.	(p=1)	
	
In	the	aspect	of	Fuhrman	grade,	the	numbers	of	cases	with	high	and	low	expression	
of	 IL-22	were	17	and	29	 in	 low	Fuhrman	grade	(G1	and	G2)	group.	However,	these	
two	 values	 were	 11	 and	 3	 in	 patients	 with	 high	 Fuhrman	 grade	 (G3	 and	 G4).	
According	 to	Fisher’s	exact	 test	analysis,	 there	was	 significance	of	 IL-22	expression	
between	low	Fuhrman	grade	group	and	high	Fuhrman	grade	group.	(p=0.0126)	 	
	
Similarly,	 there	 was	 also	 a	 significant	 difference	 in	 IL-22	 expression	 in	 terms	 of	
primary	 T	 stage	 between	 low	 stage	 (pT1	 and	 pT2)	 and	 high	 stage	 (pT3	 and	 pT4).	
Same	as	Fuhrman	grade,	there	were	17	and	29	cases	expressing	IL-22	in	high	levels	
and	 low	 levels	 in	 low	primary	T	 stage	group,	and	11	cases	expressing	high	 IL-22	 in	
high	T	stage	group,	which	only	3	patients	had	IL-22	low	expression.	 	
	
As	 to	 necrosis,	 in	 patients	whose	 tumor	without	 necrosis,	 there	were	 18	 patients	
expressing	high	levels	of	IL-22	and	the	other	26	cases	expressing	low	levels	of	IL-22,	
while	 in	 patients	 with	 necrosis,	 these	 values	 were	 10	 and	 6.	 There	 was	 no	
significance	of	IL-22	expression	between	these	two	groups.	(p=0.1569)	 	
	
When	it	comes	to	venous	thrombus,	there	were	23	cases	without	venous	thrombus	
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expressing	 high	 levels	 of	 IL-22,	 and	 this	 number	 was	 29	 in	 low	 levels	 of	 IL-22.	
However,	 in	venous	thrombus	present	patients,	5	of	them	expressing	high	levels	of	
IL-22	 and	 the	 other	 3	 expressing	 low	 levels	 of	 IL-22.	 Also	 here	 there	 was	 no	
significance	between	two	groups.	(p=0.4544)	 	
	
Next,	 the	 correlation	 between	 expression	 of	 IL-22	 and	 relapse	 of	 disease	 was	
analyzed.	As	shown	in	the	table	5,	among	patients	who	did	not	suffer	relapse,	there	
were	 15	 and	 27	 cases	 expressing	 high	 levels	 of	 IL-22	 and	 low	 levels	 of	 IL-22,	
respectively.	While	in	patients	that	relapsed,	these	two	numbers	turned	to	12	and	6.	
Interestingly,	 this	 difference	 was	 statistically	 significant	 between	 two	 groups	
(p=0.0463).	 	
	
A	similar	result	was	shown	in	vital	status,	there	were	37	patients	still	alive	at	the	end	
of	 our	 follow-up	 period,	 among	 them	 12	 patients	 showed	 a	 high	 level	 IL-22	
expression,	 the	other	25	patients	showed	 low	 level	of	 IL-22	expression.	 In	patients	
who	were	dead	during	the	 follow-up	period,	 the	numbers	of	cases	expressing	high	
levels	and	low	levels	of	 IL-22	were	16	and	7.	Similar	to	result	of	relapse,	there	was	
also	statistical	significance	between	two	different	groups.	(p=0.0077)	
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Table	5Correlations	between	IL-22	expression	and	clinicopathologic	characteristics	
	
IL-22	High	 IL-22	Low	 p-value	
Age	
	 	
0.2988	
<=60	 15	 12	
	>60	 13	 20	
	Sex	
	 	
1	
Male	 14	 16	
	Female	 14	 16	
	Fuhrman	grade	
	 	
0.0126	
Low(G1/G2)	 17	 29	
	High(G3/G4)	 11	 3	
	Primary	T	stage	
	 	
0.0126	
Low(pT1/pT2)	 17	 29	
	High(pT3/pT4)	 11	 3	
	Necrosis	
	 	
0.1569	
Absent	 18	 26	
	Present	 10	 6	
	Venous	thrombus	
	 	
0.4544	
Absent	 23	 29	
	Present	 5	 3	
	Relapse	
	 	
0.0463	
Absent	 15	 27	
	Present	 12	 6	
	Vital	status	
	 	
0.0077	
Alive	 12	 25	
	Dead	 16	 7	
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3.6	 Correlations	 between	 IL-22RA1	 expression	 and	 ccRCC	
patients’	clinicopathologic	characteristics	
As	shown	in	Table	6,	in	the	aspect	of	age,	in	the	group	which	patients	aged	equal	or	
less	 than	 60	 years	 old,	 there	 were	 15	 cases	 and	 12	 cases	 with	 high	 IL-22RA1	
expression	and	 low	IL-22RA1	expression,	respectively.	However,	 in	the	other	group	
which	patients	were	more	 than	60	years	old,	 the	number	of	 cases	expressing	high	
levels	and	low	levels	of	IL-22RA1	were	19	and	14.	There	was	no	significant	difference	
of	IL-22RA1	expression	between	two	groups.	(p=1)	 	
	
Regarding	gender,	there	were	21	cases	and	9	cases	expressing	a	high	and	low	level	of	
IL-22RA1,	respectively	in	male	patients.	Meanwhile	there	were	also	13	cases	and	17	
cases	with	high	and	low	expression	of	IL-22RA1	in	female	patients.	This	meant	there	
was	no	significance	of	IL-22R1	expression	between	genders	(p=0.0673).	 	
	
In	the	aspect	of	Fuhrman	grade,	the	numbers	of	cases	with	high	and	low	expression	
of	 IL-22RA1	were	 21	 and	 25	 in	 low	 Fuhrman	 grade	 (G1	 and	 G2)	 group.	 However,	
these	two	values	were	13	and	1	 in	patients	with	high	Fuhrman	grade	(G3	and	G4).	
According	 to	 Fisher’s	 exact	 test	 analysis,	 there	 was	 a	 significance	 of	 IL-22RA1	
expression	 between	 low	 Fuhrman	 grade	 group	 and	 high	 Fuhrman	 grade	 group	
(p=0.0018).	 	
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However,	 there	was	no	 significant	 difference	 (p=0.0718)	 of	 IL-22RA1	expression	 in	
terms	of	primary	T	stage	between	low	stage	(pT1	and	pT2)	and	high	stage	(pT3	and	
pT4).	There	were	23	and	23	cases	expressing	IL-22RA1	in	high	levels	and	low	levels,	
respectively	 in	 low	primary	T	stage	group,	and	11	cases	expressed	high	IL-22RA1	in	
high	T	stage	group,	which	only	3	patients	had	IL-22RA1	low	expression.	 	
	
As	 to	 necrosis,	 in	 patients	 whose	 tumor	 lacked	 necrosis,	 there	 were	 22	 patients	
expressing	high	levels	of	IL-22RA1	and	low	levels	of	IL-22RA1	each,	while	in	necrosis	
present	 patients,	 there	 were	 12	 patients	 expressed	 a	 high	 level	 of	 IL-22RA1	 and	
another	 4	 cases	 expressed	 a	 low	 level	 of	 IL-22RA1.	 Obviously,	 the	 difference	 of	
IL-22RA1	 expression	 was	 not	 statistically	 significant	 between	 these	 two	 groups.	
(p=0.1399)	 	
	
In	 terms	 of	 venous	 thrombus,	 there	 were	 28	 cases	 without	 venous	 thrombus	
expressing	high	levels	of	IL-22RA1,	and	this	number	was	24	in	low	levels	of	IL-22RA1.	
However,	 in	venous	thrombus	present	patients,	6	of	them	expressing	high	levels	of	
IL-22RA1	 and	 the	 other	 2	 expressing	 low	 levels	 of	 IL-22RA1.	 The	 difference	 of	
IL-22RA1	 expression	 was	 not	 statistically	 significant	 between	 these	 two	 groups.	
(p=0.4463)	 	
	
The	correlation	between	expression	of	IL-22RA1	and	relapse	was	analyzed.	As	shown	
in	 the	 table	 5,	 in	 patients	who	 did	 not	 have	 relapse,	 there	were	 18	 and	 24	 cases	
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expressing	high	levels	of	IL-22RA1	and	low	levels	of	IL-22RA1,	respectively.	While	in	
patients	 that	 relapsed,	 these	 two	 numbers	 became	 16	 and	 2.	 Interestingly,	 the	
difference	 of	 IL-22RA1	 expression	 was	 statistically	 significant	 between	 these	 two	
groups.	(0.0014).	 	
	
A	similar	result	was	seen	in	terms	of	vital	status,	there	were	37	patients	still	alive	at	
the	end	of	follow-up	period,	among	them	21	patients	showed	high	levels	of	IL-22RA1	
expression,	 the	 other	 16	 patients	 showed	 low	 levels	 of	 IL-22RA1	 expression.	 In	
patients	 who	 were	 dead	 during	 the	 follow-up	 period,	 the	 numbers	 of	 cases	
expressing	high	levels	and	low	levels	of	IL-22RA1	were	18	and	5,	respectively.	Similar	
to	relapse,	this	difference	was	statistically	significant	between	two	groups.	(p=0.015)	
	
Table	6	Correlations	between	IL-22RA1	expression	and	clinicopathologic	characteristics	
	
IL-22RA1	High	 IL-22RA1	Low	 p-value	
Age	
	 	
1	
<=60	 15	 12	
	>60	 19	 14	
	Sex	
	 	
0.0673	
Male	 21	 9	
	Female	 13	 17	
	Fuhrman	grade	
	 	
0.0018	
Low(G1/G2)	 21	 25	
	High(G3/G4)	 13	 1	
	Primary	T	stage	
	 	
0.0718	
Low(pT1/pT2)	 23	 23	
	High(pT3/pT4)	 11	 3	
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Necrosis	
	 	
0.1399	
Absent	 22	 22	
	Present	 12	 4	
	Venous	thrombus	
	 	
0.4463	
Absent	 28	 24	
	Present	 6	 2	
	Relapse	
	 	
0.0014	
Absent	 18	 24	
	Present	 16	 2	
	Vital	status	
	 	
0.0150	
Alive	 16	 21	
	Dead	 18	 5	
		
3.7	 Correlations	 between	 IL-22	 and	 ccRCC	 patients’	 overall	
survival	and	disease-free	survival	 	
As	mentioned	above,	patients	were	 separated	 to	 two	groups,	 IL-22	 low	group	and	
IL-22	 high	 group,	 depending	 on	 IL-22	 expression.	 First,	 the	 overall	 survival	 was	
compared	 between	 these	 two	 groups.	 As	 shown	 in	 Figure	 14A,	 the	 difference	 of	
overall	 survival	 was	 statistically	 significant	 between	 two	 groups	 (p=0.0031).	 High	
expression	of	 IL-22	was	associated	with	shorter	overall	survival	compared	with	 low	
expression	of	 IL-22.	Log-rank	test	showed	Chi-square	value	was	8.719,	hazard	ratio	
was	 3.616,	 95%	 CI	 of	 ratio	 was	 1.541	 to	 8.488.	 Next,	 the	 disease-free	 survival	
between	two	groups	was	compared.	The	difference	was	also	significance	(p=0.0422).	
High	expression	of	IL-22	was	associated	with	shorter	disease-free	survival	compared	
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with	 low	 expression	 of	 IL-22.	 Log-rank	 test	 showed	 Chi-square	 value	 was	 4.128,	
hazard	ratio	was	2.641,	95%	CI	of	ratio	was	1.035	to	6.741.	(Figure	14B)	Patients	with	
high	 expression	 of	 IL-22	 had	 a	 shorter	 overall	 survival	 and	 disease-free	 survival	
compared	to	patients	with	low	expression	of	IL-22.	
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Figure	14	IL-22	Kaplan-Meier	survival	estimates.	A	Patients	with	low	IL-22	expression	have	a	
better	 overall	 survival.	 B	 Patients	 with	 low	 IL-22	 expression	 have	 a	 better	 disease-free	
survival.	 	
A	
B	
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3.8	Correlations	between	IL-22RA1	and	ccRCC	patients’	overall	
survival	and	disease-free	survival	
In	 the	 same	 way,	 the	 overall	 survival	 and	 disease-free	 survival	 were	 compared	
between	 two	 groups	 which	 expressing	 low	 levels	 of	 IL-22RA1	 and	 high	 levels	 of	
IL-22RA1.	As	shown	 in	Figure	15A,	 the	difference	of	overall	 survival	was	significant	
between	these	two	groups	of	patients	(p=0.0196).	High	expression	of	IL-22RA1	was	
associated	 with	 poor	 patient	 overall	 survival	 compared	 with	 low	 expression	 of	
IL-22RA1.	Chi-square	was	analyzed	by	 log-rank	 test,	which	was	5.451.	Hazard	 ratio	
was	 2.671,	 95%	 CI	 of	 ratio	 was	 1.171	 to	 6.095.	 Similarly,	 the	 difference	 of	
disease-free	 survival	was	 also	 significant	 between	 high	 and	 low	 levels	 of	 IL-22RA1	
expression	 patients	 (p=0.0036),	 high	 expression	 of	 IL-22RA1	 was	 associated	 with	
poor	 patient	 disease-free	 survival	 compared	 with	 low	 expression	 of	 IL-22RA1.	
Log-rank	 test	 showed	Chi-square	was	8.470.	Hazard	 ratio	was	3.978	and	95%	CI	of	
ratio	 was	 1.570	 to	 10.080	 (Figure	 15B).	 Patients	 with	 high	 expression	 level	 of	
IL-22RA1	 had	 a	 shorter	 overall	 survival	 and	 disease-free	 survival	 compared	 to	
patients	with	low	expression	pattern	of	IL-22RA1	 	
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Figure	15	 IL-22R1	Kaplan-Meier	survival	estimates.	A	Patients	with	low	expression	level	of	
IL-22RA1	have	a	better	overall	survival.	B	Patients	with	low	expression	level	of	IL-22RA1	have	
a	better	disease-free	survival.	 	
A	
B	
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3.9	 Correlations	 between	 Ki-67	 and	 ccRCC	 patients’	 overall	
survival	and	disease-free	survival	
Moreover,	the	overall	survival	and	disease-free	survival	between	patients	expressing	
low	 levels	and	high	 levels	of	Ki-67	cells	within	 tumors	was	compared.	As	 shown	 in	
Figure	 16A,	 the	 difference	 of	 overall	 survival	 was	 significant	 between	 these	 two	
groups	of	patients	(p=0.0461).	High	expression	of	Ki-67	was	associated	with	shorter	
patient	 overall	 survival	 compared	 with	 low	 expression	 of	 Ki-67.	 Chi-square	 was	
analyzed	by	log-rank	test,	which	was	3.976.	Hazard	ratio	was	2.309,	95%	CI	of	ratio	
was	 1.014	 to	 5.258.	 Similarly,	 the	 difference	 of	 disease-free	 survival	 was	 also	
significant	between	patients	with	high	and	low	levels	of	Ki-67	expression	(p=0.0171).	
High	 expression	 of	 Ki-67	was	 associated	with	 shorter	 patient	 disease-free	 survival	
compared	with	low	expression	of	Ki-67.	Log-rank	test	showed	Chi-square	value	was	
5.681,	hazard	ratio	was	3.096	and	95%	CI	of	ratio	was	1.222	to	7.839.	 (Figure	16B)	
Patients	 with	 high	 expression	 level	 of	 Ki-67	 had	 a	 shorter	 overall	 survival	 and	
disease-free	survival	compared	to	patients	with	low	expression	pattern	of	Ki-67.	 	
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Figure	16	 	 Ki-67	Kaplan-Meier	 survival	 estimates.	A	Patients	with	low	expression	level	of	
ki-67	 have	 a	 better	 overall	 survival.	 B	 Patients	 with	 low	 expression	 level	 of	 ki-67	 have	 a	
better	disease-free	survival.	 	
A	
B	
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3.10	 Correlations	 between	 Caspase-3	 and	 ccRCC	 patients’	
overall	survival	and	disease-free	survival	
In	addition,	a	comparison	between	patients	expressing	low	levels	and	high	levels	of	
caspase-3	 was	 performed.	 As	 shown	 in	 Figure	 17A,	 there	 was	 no	 significance	
(p=0.4953)	in	the	difference	of	overall	survival	between	these	two	groups	of	patients.	
However,	 there	 was	 significance	 between	 them	 in	 disease-free	 survival,	 p=0.0432	
(Figure	17B).	High	expression	of	caspase-3	was	associated	with	shorter	disease-free	
survival	of	ccRCC	patients.	Chi-square	value	was	4.078,	hazard	ratio	was	2.727,	and	
95%	CI	of	ratio	was	1.031	to	7.211.	Patients	with	high	expression	level	of	caspase-3	
had	a	shorter	disease-free	survival	compared	to	patients	with	low	expression	pattern	
of	caspase-3.	 	
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Figure	 17	 	 Casspase-3	 Kaplan-Meier	 survival	 estimates.	A	 Patients	with	 high	 expression	
and	 low	 expression	 level	 of	 caspase-3	 have	 no	 significant	 difference	 in	 overall	 survival.	 B	
Patients	with	low	expression	level	of	caspase-3	have	a	better	disease-free	survival.	 	
	
A	
B	
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3.11	Multivariate	Cox	proportional	hazards	regression	models	
for	ccRCC	patients’	overall	survival	and	disease-free	survival	
As	 list	 in	 Table	 7	 and	 8,	 the	 independent	 prognostic	 values	 of	 various	 parameters	
were	 assessed	 via	 the	 multivariate	 Cox	 proportional	 hazards	 model.	 Parameters	
included	age	(<=60	years	vs.	>60	years),	sex	(male	vs.	female),	Fuhrman	grade	(G1/2	
vs.	G3/4),	 stage	 (pT1/2	 vs.	 pT3/4),	 necrosis	 (absent	 vs.	 present),	 venous	 thrombus	
(absent	 vs.	 present),	 IL-22	 expression	 (high	 vs.	 low),	 IL-22RA1	 expression	 (high	 vs.	
low),	 Ki-67	 expression	 (high	 vs.	 low)	 and	 caspase	 3	 expression	 (high	 vs.	 low).	 The	
results	 showed	 that	 tumor	 stage	 (HR,	 6.046;	 95%	 CI,	 0.041	 to	 0.659;	 p=0.011),	
necrosis	 in	 tumor	 (HR,	 6.78;	 95%	 CI,	 1.562	 to	 29.433;	 p=0.011)	 and	 IL-22RA1	
expression	 (HR,	 3.242;	 95%	 CI,	 0.096	 to	 0.991;	 p=0.048)	 were	 independent	
prognostic	 markers	 for	 mortality	 in	 patients	 with	 ccRCC	 after	 controlling	 for	
conventional	clinicopathologic	 factors.	Meanwhile,	Fuhrman	grade	 (HR,	5.780;	95%	
CI,	 0.035	 to	 0.853;	 p=0.031),	 tumor	 stage	 (HR,	 55.296;	 95%	 CI,	 0.001	 to	 0.258;	
p=0.003),	 venous	 thrombus	 (HR,	 22.082;	 95%	 CI,	 1.584	 to	 36.722;	 p=0.021)	 and	
IL-22RA1	expression	(HR,	75.355;	95%	CI,	1.87	to	20.798;	p=0.022)	were	independent	
prognostic	marker	for	recurrence.	
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Table	7	 	 Multivariable	Cox	proportional	hazards	regression	model	for	overall	survival	 	
Parameter       Variable        HR 95% CI           p Value 
Age <=60 vs. >60 0.938 0.382 to 2.301 0.889 
Sex male vs. female 2.557 0.906 to 7.213 0.076 
Fuhrman grade G1/2 vs. G3/4 2.019 0.510 to 7.998 0.317 
Stage p1/2 vs. p3/4 6.046 1.516 to 24.102 0.011 
Necrosis absent vs. present 6.780 1.562 to 29.433 0.011 
Venous thrombus absent vs. present 2.143 0.488 to 9.419 0.313 
IL-22 high vs. low 1.738 0.461 to 6.549 0.414 
IL-22RA1 high vs. low 3.242 1.010 to 10.412 0.048 
Ki-67 high vs. low 0.819 0.274 to 2.447 0.720 
Caspase-3 high vs. low 0.565 0.173 to 1.843 0.344 
	
Table	8	Multivariable	Cox	proportional	hazards	regression	model	for	disease-free	survival	
Parameter Variable  HR 95% CI         p Value 
Age <=60 vs. >60 0.629 0.141 to 2.798 0.543 
Sex male vs. female 1.950 0.235 to 16.192 0.536 
Fuhrman grade G1/2 vs. G3/4 5.780 1.172 to 28.518 0.031 
Stage p1/2 vs. p3/4 55.296 3.883 to 787.444 0.003 
Necrosis absent vs. present 0.273 0.026 to 2.868 0.279 
Venous thrombus absent vs. present 22.082 1.584 to 307.906 0.021 
IL-22 high vs. low 5.698 0.884 to 36.772 0.067 
IL22-RA1 high vs. low 75.355 1.870 to 3037.342 0.022 
Ki-67 high vs. low 0.478 0.048 to 4.760 0.529 
Caspase-3 high vs. low 4.773 0.155 to 147.125 0.372 
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4. Discussion	
In	this	study,	we	hypothesized	that:	1.	The	expression	of	IL-22-IL-22RA1	axis	proteins	
is	 correlated	with	 ccRCC	 patients’	 overall	 survival	 and	 disease-free	 survival	 in	 The	
Cancer	Genome	Atlas	dataset.	To	this	end,	we	analyzed	the	clinical	and	genomic	data	
of	 ccRCC	provided	by	 TCGA	using	 the	 cBioPortal	 resource.	We	 found	 that	patients	
with	 alterations	 in	 IL-22	 or	 IL-22RA1	 expression	 had	 a	 significantly	 shorter	 overall	
survival	and	disease-free	survival	compared	to	patients	without	alterations	 in	 IL-22	
or	 IL-22RA1	 expression;	 2.	 The	 expression	 of	 IL-22-IL-22RA1	 axis	 proteins	 is	
correlated	 with	 clinicopathological	 characteristics	 of	 ccRCC	 patients.	 To	 verify	 this	
hypothesis,	we	estimated	the	expression	of	IL-22	and	IL-22RA1	in	our	own	cohort	of	
ccRCC	 cases	 and	 correlated	 the	 expression	 with	 clinicopathological	 characteristics	
(age,	sex,	Fuhrman	grade,	primary	T	stage,	present	of	necrosis,	venous	thrombus	and	
relapse)	of	ccRCC	patients.	The	results	showed	that	IL-22	expression	was	correlated	
with	Fuhrman	grade,	primary	T	stage,	relapse	and	vital	status	of	ccRCC	patients.	And	
IL-22RA1	expression	was	associated	with	Fuhrman	grade,	relapse,	and	vital	status	of	
ccRCC	 patients.	 3.	 ccRCC	 patients	 with	 lower	 expression	 level	 of	 IL-22,	 IL-22RA1,	
IL-22BP,	Ki-67,	Caspase-3	have	a	longer	overall	survival	time	and	disease-free	survival	
time.	To	verify	this	point,	we	estimated	the	expression	of	IL-22,	IL-22R,	and	IL-22BP,	
Ki-67	and	Caspase-3	in	human	ccRCC	tissues	and	correlated	the	expression	with	the	
outcomes	of	 ccRCC	patients	 in	our	patients’	 cohort.	 Immunohistochemical	 staining	
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detected	 IL-22,	 IL-22RA1,	Ki-67,	and	caspase-3	positive	 tumor	 cells,	but	no	 IL-22BP	
positive	 cell	 was	 detected.	 The	 result	 showed	 that	 ccRCC	 patients	 with	 high	
expression	of	IL-22	had	a	poor	overall	survival	and	disease-free	survival	compared	to	
patients	 with	 low	 expression	 of	 IL-22.	 This	 was	 true	 also	 for	 IL-22RA1	 and	 Ki-67.	
However,	 ccRCC	 patients	 with	 high	 expression	 of	 caspase-3	 only	 showed	 a	
significantly	 shorter	 disease-free	 survival,	 but	 no	 change	 in	 the	 overall	 survival.	 4.	
IL-22RA1	 and	 IL-22	 are	 independent	 predictive	 factors	 for	 prognosis	 of	 ccRCC	
patients.	To	this	purpose,	multivariate	cox	proportional	hazards	models	were	used	to	
analyze	the	impact	of	prognostic	factors	on	overall	survival	and	disease-free	survival.	
The	result	revealed	that	IL-22RA1	but	not	IL-22,	is	an	independent	predictive	factor	
for	prognosis	of	ccRCC	patients.	 	
	
The	 clinical	 behavior	 of	 ccRCC	 can	 be	 estimated	 by	 a	 combination	 of	 multiple	
prognostic	factors.	Accurate	outcome	prediction	for	patients	with	ccRCC	is	important	
for	treatment	stratification.	Multiple	clinical	and	pathological	variables	are	crucial	in	
predicting	outcome	 in	patients	with	 ccRCC.	Among	 them,	 the	pathological	 stage	 is	
recognized	 as	 one	 of	 the	 most	 important	 variables	 (Javidan,	 Stricker	 et	 al.	 1999,	
Gettman,	Blute	et	 al.	 2001).	However,	 some	other	 features	 such	as	 tumor	nuclear	
grade	and	histological	 subtype	also	play	 an	 important	 role	 in	 the	outcome.	 Tumor	
stage,	 nuclear	 grading	 and	 the	 presence	 of	 tumor	 necrosis	 are	 considered	 as	 the	
major	 prognostic	 indicators	 (Frank,	 Blute	 et	 al.	 2002,	 Delahunt,	 McKenney	 et	 al.	
2013)	
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Moreover,	the	tumor	stage,	size,	grade,	and	necrosis	(SSIGN)	score	was	reported	first	
in	 2002	 for	 clinicians	 to	 assess	 the	 effects	 of	 tumor	 characteristics	 on	outcome	 so	
that	to	be	used	to	improve	patient	management,	stratify	ccRCC	patients	for	clinical	
trials	 to	estimate	 the	efficacy	of	adjuvant	 therapies	as	well	as	develop	appropriate	
postoperative	surveillance	programs	(Frank,	Blute	et	al.	2002).	 	
	
The	 Fuhrman	 grade	 has	 gained	 widespread	 adoption	 in	 clinical	 practice	 after	
Fuhrman’s	 report	 in	 1982	 (Fuhrman,	 Lasky	 et	 al.	 1982),	 which	 is	 based	 on	 tumor	
nuclear	 size,	 shape,	 and	 prominence	 of	 nucleoli.	 Following	 studies	made	 Fuhrman	
grade	more	convincible	by	testing	against	survival	for	large	series	of	tumors	divided	
based	 on	 RCC	 subtype	 (Delahunt	 2009).	 In	 studies	 focus	 on	 ccRCC,	 significant	
differences	in	survival	were	noted	between	each	grade	or	combined	grade	1	and	2,	
grade	3	and	4	(Ficarra,	Righetti	et	al.	2001,	Kim,	Cho	et	al.	2004,	Ficarra,	Martignoni	
et	al.	2005).	 	
	
In	 spite	 of	 the	 effort	 of	 concerning	 studies	 on	 Fuhrman	 grade,	 there	 are	
controversies	on	its	reliability.	Some	researchers	demonstrated	that	Fuhrman	grade	
should	 not	 be	 regarded	 as	 a	 reliable	 prognostic	 factor.	 For	 instance,	 one	 study	
reported	that	tumor	grade	did	not	provide	additional	survival	data	once	tumor	stage	
was	assigned	(Patard,	Leray	et	al.	2005).	On	the	contrary,	several	other	studies	noted	
a	 significant	 prognostic	 role	 of	 Fuhrman	 grade.	One	 group	 reported	 that	 Fuhrman	
grade	 significantly	 associated	 with	 cancer	 stage,	 distant	 metastasis	 and	 patient	
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survival	(Ficarra,	Martignoni	et	al.	2005).	Moreover,	Ke-Hung	Tsui,	et	al.	reported	a	
correlation	between	advanced	 tumor	 stage	 and	high-grade	 lesion,	which	 indicated	
that	high	tumor	grade	might	make	tumor	more	aggressive,	thus	leading	to	high	stage,	
distant	metastasis	as	well	as	diminished	survival	rates	(Tsui,	Shvarts	et	al.	2000).	 	
	
In	 our	 study,	 the	 correlation	 between	 IL-22	 expression	 and	 ccRCC	 patients’	
clinicopathological	 characteristics	 showed	that	Fuhrman	grade	was	associated	with	
IL-22	 expression;	 a	 similar	 result	was	 obtained	 by	 correlating	 Fuhrman	 grade	with	
IL-22RA1	expression.	In	the	multivariate	Cox	proportional	hazards	regression	model,	
among	 all	 the	 variables,	 Fuhrman	 grade	 (G1/2	 vs.	 G3/4)	 was	 not	 an	 independent	
predictor	 for	 overall	 survival	 of	 ccRCC	 patients.	 However	 it	 was	 an	 independent	
prognostic	 factor	 for	 disease-free	 survival	 of	 ccRCC	 patients.	 Above	 all,	 Fuhrman	
grade	still	can	be	a	useful	predictor	of	the	outcome	of	ccRCC	patients,	especially	 in	
respect	 to	 recurrence	 prediction	 after	 surgery.	 The	 mechanism	 of	 how	 IL-22	 and	
IL-22RA1	expression	impact	Fuhrman	grade	or	the	other	way	around	is	unknown	and	
needs	further	studies	in	the	future.	 	
	
Tumor	stage	is	regarded	as	one	of	the	most	powerful	predictors	of	outcome	for	RCC	
patients	(Selli,	Hinshaw	et	al.	1983,	Delahunt,	Bethwaite	et	al.	1994).	Over	the	past	
several	decades,	in	order	to	make	it	even	more	accurate	in	patient	prognostication,	
several	evidence-based	amendments	have	been	added	to	the	TNM	staging	system	of	
RCC.	 Primary	 tumor	 size	 and	 regional	 spread	 have	 been	 regarded	 as	 significant	
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prognostic	 factors	 of	 RCC	 and	 there	 is	 a	 large	 body	 of	 evidence	 to	 indicate	 that	
tumor	 size	 can	 predict	 tumor	 infiltration	 into	 the	 kidney	 sinus,	 therefore	 is	 a	
dependent	prognostic	feature	(Delahunt	2009).	 	
	
Numerous	studies	on	the	prognostic	significance	of	tumor	size	have	been	reported.	
From	 the	 results	 of	 present	 study,	 there	 was	 a	 significant	 correlation	 between	
primary	T	stage	and	IL-22	expression.	Cases	expressed	a	higher	level	of	IL-22	tend	to	
have	 a	 higher	 stage.	 However,	 this	 correlation	 was	 not	 observed	 in	 IL-22RA1,	
although	 the	 p-value	 was	 only	 a	 little	 higher	 than	 0.05.	 Interestingly	 but	 not	
surprisingly,	multivariate	 Cox	 proportional	 hazards	 regression	 analysis	 implied	 that	
primary	 tumor	 stage	 is	 an	 independent	 prognostic	 factor	 for	 both	 overall	 survival	
and	disease-free	survival	in	ccRCC	patients.	ccRCC	patients	with	lower	primary	tumor	
stage	 may	 have	 a	 better	 outcome.	 This	 finding	 was	 consistent	 to	 previous	
investigations	by	other	groups.	
	
Coagulative	tumor	necrosis	was	first	recognized	as	a	prognostic	marker	of	advanced	
RCC	in	the	1970s	(Amtrup,	Hansen	et	al.	1974,	Mancilla-Jimenez,	Stanley	et	al.	1976).	
Coagulative	 necrosis	 is	 the	 most	 common	 form	 of	 necrosis.	 Typical	 necrosis	 has	
homogeneous	clusters,	sheets	of	dead	as	well	as	degraded	tumor	cells	that	coalesce	
into	 an	 amorphous	 coagulum	 (Sengupta,	 Lohse	 et	 al.	 2005).	 One	 large	 cohort	
research	 with	 3009	 patients	 was	 performed	 to	 characterize	 tumor	 necrosis	 as	 a	
prognostic	feature	of	RCC,	and	indicated	that	histologic	coagulative	tumor	necrosis	is	
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an	independent	predictor	of	prognosis	for	ccRCC	and	chromophobe	RCC	and	that	the	
presence	of	necrosis	 indicated	an	 increased	hazard	 for	death	 from	RCC	 (Sengupta,	
Lohse	et	al.	2005).	However,	there	are	some	other	studies	with	different	conclusions.	
One	 study	 by	 Foria	 et	 al.	 shows	 that	 extensive	 necrosis	 in	 RCC	may	 imply	 better	
short-term	 prognosis,	 but	 this	 predictive	 value	 was	 abolished	 after	 adjusting	 for	
tumor	 pTNM	 stage	 (Foria,	 Surendra	 et	 al.	 2005).	 Additionally,	 Leibovitch	 et	 al.	
performed	 a	 consecutive	 retrospective	 study	 of	 173	 RCC	 patients	 after	 radical	
nephrectomy,	 showing	 that	 extensive	 necrosis	 was	 not	 related	 to	 kidney	 tumor	
biology,	 but	 might	 rather	 reflect	 the	 relation	 between	 tumor	 size	 and	 vascularity	
(Leibovitch,	Lev	et	al.	2001).	
	
In	our	 current	 study,	 as	one	of	 the	 clinicopathological	 features	 to	be	assessed,	we	
first	correlated	the	expression	of	both	IL-22	and	IL-22RA1	with	intratumoral	necrosis	
and	 did	 not	 find	 a	 significant	 correlation	 between	 necrosis	 and	 the	 expression	 of	
IL-22	 or	 IL-22RA1.	Moreover,	 the	multivariate	 Cox	 proportional	 hazards	 regression	
analysis	 for	 disease-free	 survival	 implied	 that	 necrosis	 is	 not	 an	 independent	
predictor	of	disease-free	survival,	whereas	it	was	an	independent	predictor	of	overall	
survival	 for	 ccRCC	 patients.	 The	 cause	 of	 extensive	 necrosis	 in	 RCC	 is	 not	 well	
understood.	 Normally	 it	 is	 not	 very	 common	 for	 RCC	 tumors	 to	 show	 extensive	
necrosis,	and	only	1.6%	of	all	the	RCC	cases	diagnosed	with	extensive	necrosis	during	
8	years	in	a	regional	hospital,	and	it	is	a	kind	of	tumor	that	rarely	show	spontaneous	
regression	 (Hamid	 and	 Poller	 1998).	 The	 reasons	 for	 this	 phenomenon	 include	
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auto-infarction	 which	 results	 from	 renal	 vein	 thrombosis,	 the	 existence	 of	 renal	
artery	atherosclerosis,	tumor	growth	exceeding	the	vascular	supply,	or	mechanisms	
of	the	autoimmune	anti-tumor	response	(Childs,	Chernoff	et	al.	2000).	One	previous	
report	 noted	 that	 extensive	 tumor	 necrosis	 might	 be	 result	 of	 renal	 tumor	
spontaneous	regression	(Hamid	and	Poller	1998).	Since	some	studies	had	too	small	
number	of	cases	to	perform	valuable	statistical	analysis	to	estimate	the	correlation	
between	tumor	necrosis	and	prognosis,	more	studies	should	focus	on	the	pattern	of	
necrosis	with	RCC	prognosis	as	well	as	the	mechanism	of	necrosis	or	regression.	 	
	
As	to	venous	thrombus,	there	are	5%	to	15%	of	RCC	patients	with	venous	thrombus	
extension,	 and	 20%	 to	 50%	 of	 these	 patients	 present	 with	 metastasis,	 and	 the	
prognosis	for	this	subset	is	poor	(Blute,	Leibovich	et	al.	2004,	Terakawa,	Miyake	et	al.	
2007,	Wagner,	Patard	et	al.	2009,	Miyake,	Terakawa	et	al.	2012).	One	study	focus	on	
venous	 thrombus	 of	 RCC	 demonstrated	 that	 inferior	 vena	 cava	 tumor	 thrombus	
volume	 (IVC-TV)	 may	 represent	 a	 clinical-associated	 variable	 for	 assessment	 of	
perioperative	complications,	disease	progression,	as	well	as	overall	survival,	and	has	
a	 greater	 predictive	 value	 in	 RCC	 than	 the	 tumor	 size	 and	 metastases	
(Zargar-Shoshtari,	 Sharma	 et	 al.	 2015).	 Nevertheless,	 another	 study	 indicated	 that	
venous	 tumor	 thrombus	 consistency	 was	 not	 predictive	 of	 overall	 survival	 in	 RCC	
patients.	 They	 evaluated	 the	 prognostic	 value	 of	 venous	 tumor	 thrombus	
consistency	 in	 147	 RCC	 patients	 with	 or	 without	 venous	 tumor	 thrombus,	 result	
showed	that	venous	tumor	thrombus	consistency	was	not	predictive	of	survival,	and	
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did	 not	 enhance	 the	 performance	 of	 a	multivariable	model	 which	 included	 series	
informative	predictors	(Antonelli,	Sodano	et	al.	2015).	 	
	
In	 our	 present	 study,	 the	 result	 of	 the	 correlation	 between	 IL-22	 expression	 and	
clinicopathological	 variables	 showed	 no	 significant	 association	 between	 IL-22	
expression	and	present	of	venous	thrombus.	The	same	was	true	for	correlation	with	
IL-22RA1	 expression	 and	 with	 other	 clinicopathological	 characteristics.	 Moreover,	
the	 multivariate	 Cox	 proportional	 hazards	 regression	 model	 for	 overall	 survival	
indicated	 that	 venous	 thrombus	 consistency	 is	 not	 an	 independent	 predictor	 for	
overall	 survival	 of	 ccRCC	 patients.	 Interestingly,	 the	 multivariate	 Cox	 proportional	
hazards	 regression	model	 for	 disease-free	 survival	 revealed	 that	 venous	 thrombus	
consistency	 is	 an	 independent	predictor	of	 disease-free	 survival	 of	 ccRCC	patients.	
Considering	all	the	conclusions	drawn	from	previous	studies	along	with	our	findings,	
further	 research,	 especially	 including	 large	 case	 cohorts	 with	 long-term	 follow-up	
periods	 are	 still	 required	 to	 decide	 whether	 venous	 thrombus	 is	 an	 independent	
predictor	of	survival	of	RCC	patients.	 	 	
	
In	spite	of	all	the	conclusions	above,	ccRCC	is	an	extremely	complicated	disease.	The	
disease-free	survival	and	overall	survival	of	ccRCC	patients	are	still	not	satisfactory.	
In	 the	 past	 decade,	 intensive	 molecular	 research	 has	 provided	 substantial	 insight	
into	the	biological	behavior	of	RCC	and	is	beginning	to	shape	clinical	practice	(Shariat	
and	 Xylinas	 2012).	 The	 increasing	 number	 of	 patients	 raises	 the	 need	 for	 new	
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molecular	 markers	 to	 evaluate	 the	 risk	 of	 death	 as	 well	 as	 recurrence.	 Thus,	
identification	and	incorporation	of	these	molecular	markers	is	considered	to	play	an	
important	role	in	the	future.	 	
	
There	 have	 been	 varieties	 of	 serum	 and	 tissue	 molecular	 biomarkers	 that	 are	
suggested	 as	 potential	 prognostic	 markers.	 Rabjerg	 et	 al.	 used	 TaqMan	 assays	 to	
identify	superior	prognostic	makers	in	a	long-term	follow-up	study	and	they	showed	
a	strong	correlation	between	high	expression	levels	of	SPP1	and	CSNK2A1	and	a	poor	
prognosis	in	ccRCC	patients,	while	DEFB1	expression	was	on	the	contrary	associated	
with	a	better	DFS	 (Rabjerg,	Bjerregaard	et	 al.	 2016).	 Several	molecular	biomarkers	
have	been	identified	to	guide	therapy.	The	most	promising	results	so	far	are	VEGF,	
VEGF	 receptors,	 CAIX	 (Carbonic	 anhydrase	 IX),	 HIF-1α	 and	 VHL	 expression	 of	 the	
tumor	(Czarnecka,	Kukwa	et	al.	2014).	 	
	
Among	 various	 molecular	 biomarkers	 that	 have	 been	 identified	 so	 far,	 Ki-67	 is	
regarded	 as	 a	 significant	 prognostic	 marker	 in	 several	 neoplasms,	 including	 RCC	
(Gerdes	 1990).	 Higher	 Ki-67	 expression	 predicted	 shorter	 survival	 of	 RCC	
(Rioux-Leclercq,	 Turlin	et	 al.	 2000,	Visapaa,	Bui	 et	 al.	 2003).	Gayed	et	 al.	 validated	
Ki-67	 as	 a	 convictive	 independent	molecular	marker	 to	 predict	 outcomes	 in	 ccRCC	
patients	(Gayed,	Youssef	et	al.	2014).	Another	study	by	Tollefson	et	al.	reported	that	
both	 Ki-67	 and	 coagulative	 tumor	 necrosis	 are	 independent	 predictors	 of	 poor	
outcome	for	ccRCC	patients,	however,	Ki-67	and	coagulative	tumor	necrosis	should	
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not	be	regarded	as	surrogates	for	each	other,	and	both	of	them	should	be	taken	into	
account	when	generating	prognosis	 for	 ccRCC	patients	 (Tollefson,	 Thompson	et	 al.	
2007).	 In	 the	 present	 study,	 we	 measured	 the	 expression	 of	 Ki-67	 in	 60	 ccRCC	
patients	and	assess	the	correlation	between	Ki-67	expression	and	outcome	of	ccRCC	
patients.	 First,	 from	 the	 results	 of	 Kaplan-Meier	 analysis,	 there	 are	 significant	
differences	 between	 high	 level	 and	 low	 level	 of	 Ki-67	 expression	 in	 both	 overall	
survival	 and	 disease-free	 survival,	 which	 revealed	 that	 ccRCC	 patients	 with	 high	
expression	 of	 Ki-67	 tend	 to	 have	 a	 poor	 prognosis.	 Nevertheless,	 the	 results	 from	
multivariate	 Cox	 proportional	 hazards	 regression	 analysis	 for	 overall	 survival	 and	
disease-free	 survival	demonstrated	 that	Ki-67	 is	not	 an	 independent	predict	 factor	
for	the	outcome	of	ccRCC	patients.	This	result	 is	somehow	inconsistent	to	some	of	
other	 studies,	 even	 though	 it	 is	not	 very	explicit	 in	 terms	of	 this	 inconformity,	 the	
relatively	 small	 number	 of	 cases	 in	 our	 study	may	 be	 one	 the	 reasons.	Moreover,	
there	 may	 be	 a	 correlation	 between	 Ki-67	 and	 the	 IL-22-IL-22R	 axis,	 so	 that	 the	
multivariate	 Cox	 proportional	 hazards	 regression	 analysis	 shows	 different	 results	
compared	 to	 studies	 not	 assessing	 the	 IL-22-IL-22R	 axis.	 Further	 studies	 should	be	
designed	 to	 identify	 whether	 there	 is	 an	 association	 between	 expression	 of	
IL-22-IL-22	axis	and	Ki-67.	 	
	
Apoptosis	 plays	 a	 crucial	 role	 in	 various	 physiological	 processes	 including	
maintenance	 of	 tissue	 homeostasis	 (Hengartner	 2000).	 Disorders	 in	 physiological	
pathways	 of	 apoptosis	 contribute	 to	 different	 diseases	 such	 as	 autoimmunity,	
79	
Discussion	
neurodegeneration	 and	 cancer	 (Reed	 1999).	 Activation	 of	 caspase-3	 can	 initiate	 a	
specific	 death-inducing	 signal	 involved	 in	 the	 normal	 apoptotic	 process	 and	 down	
regulated	expression	of	 caspase-3	 is	 correlated	with	enhanced	malignant	potential	
and	 decreased	 survival	 of	 cancer	 patients	 (Frisch	 and	 Francis	 1994,	 Glinsky	 and	
Glinsky	1996,	Kurabayashi,	Furihata	et	al.	2001,	Hsia,	Chen	et	al.	2003,	Bellini,	Cury	et	
al.	2010,	Jiang,	Gong	et	al.	2010).	We	performed	immunohistochemical	staining	for	
caspase-3	 in	 our	 tumor	 tissues	 and	 then	 analyzed	 the	 association	 between	 the	
expression	 of	 caspase-3	 and	 outcome	 of	 ccRCC	 patients.	 Kaplan-Meier	 analysis	
reveals	 that	 there	 is	 no	 significant	 difference	 between	 high	 level	 and	 low	 level	
expression	of	caspase-3	for	overall	survival.	However,	there	is	significant	difference	
between	different	levels	of	caspase-3	expression	for	disease-free	survival,	indicating	
that	high	levels	of	caspase-3	expression	in	tumor	tissue	are	associated	with	a	shorter	
disease-free,	but	not	overall	survival.	 In	addition,	the	multivariate	Cox	proportional	
hazards	 regression	 analysis	 for	 overall	 survival	 and	 disease-free	 survival	 revealed	
that	 caspase-3	 is	 not	 an	 independent	 predict	 factor	 for	 the	 outcome	 of	 ccRCC	
patients.	 	
	
IL-22BP	 is	 encoded	 by	 an	 IL-22RA1	 independent	 gene	 (Dumoutier,	 Lejeune	 et	 al.	
2001).	 IL-22BP	 is	 found	to	be	expressed	on	dendritic	cells	and	 the	expression	 level	
decreases	 when	 dendritic	 cells	 undergo	 maturation	 (Chang,	 Hanawa	 et	 al.	 2006,	
Huber,	 Gagliani	 et	 al.	 2012,	 Martin,	 Beriou	 et	 al.	 2014).	 Several	 studies	 reported	
IL-22BP	expression	 in	 lymphatic	 organs,	 the	 gastrointestinal	 system,	 the	 lungs,	 the	
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skin,	the	placenta	as	well	as	the	breast	(Dumoutier,	Lejeune	et	al.	2001,	Gruenberg,	
Schoenemeyer	 et	 al.	 2001,	 Kotenko,	 Izotova	 et	 al.	 2001,	Weiss,	Wolk	 et	 al.	 2004).	
One	 study	 reported	 that	 deficiency	 of	 IL-22BP	 leads	 to	 accelerated	 and	 increased	
tumorigenesis	in	a	colitis-associated	colon	cancer	mouse	model	(Huber,	Gagliani	et	al.	
2012).	However,	from	the	literature	no	study	was	found	on	the	correlation	between	
IL-22BP	 expression	 and	 kidney	 cancer.	 Interestingly,	 in	 the	 present	 study	 IL-22BP	
positive	staining	was	only	detected	in	adjacent	normal	kidney	tissue,	but	no	staining	
in	 tumor	 tissues,	 which	 may	 imply	 that	 IL-22BP	 has	 a	 therapeutic	 potential	 by	
blocking	 the	 function	 of	 IL-22-IL-22R1	 system	 in	 IL-22-induced	 cancer	 or	 other	
diseases.	 Further	 studies	 should	 be	 performed	 to	 clarify	 the	 mechanism	 of	 this	
phenomenon.	
	
In	this	study,	one	objective	was	to	identify	new	prognostic	and	predictive	biomarkers	
in	ccRCC.	From	others’	previous	studies,	 IL-22-IL-22R	axis	 is	associated	with	several	
types	of	cancer.	The	IL-22-IL-22R	system	seems	an	important	novel	target	in	cancer	
research.	One	study	performed	by	Xu	et	al.	revealed	a	correlation	between	Notch1	
signaling	 and	 ccRCC,	 that	 Notch1	 activation	 increased	 ccRCC	 cell	 proliferation,	
enhanced	anchorage	independent	growth	regulated	by	PI3K/Akt	pathway	(Xu,	Zhu	et	
al.	2012).	From	others’	previous	studies,	it	is	known	that	IL-22	does	not	regulate	the	
function	of	immune	cells	directly	(Wolk,	Kunz	et	al.	2004).	Instead,	IL-22	targets	cells	
at	barriers	of	the	body,	including	skin,	cells	of	the	pancreas,	digestive	and	respiratory	
systems,	 liver,	 joints	as	well	as	kidney	(Sabat,	Ouyang	et	al.	2014).	Considered	that	
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IL-22	signaling	pathway	may	be	involved	in	Notch1	signaling,	we	assumed	that	IL-22	
also	plays	a	role	in	ccRCC.	 	
	
Among	 all	 the	 studies	 focus	 on	 IL-22	 and	 cancers,	 IL-22	 is	 most	 unambiguously	
pro-tumoral	 in	 tumors	 of	 the	 gastrointestinal	 tract	 (Lim	 and	 Savan	 2014).	 Patients	
suffering	 from	gastric	 cancer	have	higher	 circulating	 frequencies	of	 IL-17	and	 IL-22	
producing	T	cells	compared	to	healthy	subjects,	and	these	T	cells	correlated	inversely	
with	the	survival	time	of	patients,	while	correlating	directly	with	the	stage	of	cancer	
(Liu,	Peng	et	al.	2012).	Renal	cell	carcinoma	is	originating	from	the	lining	epithelium	
of	proximal	convoluted	tubules	(Capitanio	and	Montorsi	2016).	In	pancreatic	cancer,	
expression	of	 IL-22	 and	 IL-22R	was	 increased	 in	pancreatic	 ductal	 adenocarcinoma	
tissue	and	both	predict	poor	patient	survival	 (Wen,	Liao	et	al.	2014).	One	study	on	
hepatocellular	 carcinoma	 indicated	 that	 high	 levels	 of	 IL-22	 in	 the	 serum	 are	
associated	with	a	poor	outcome	in	both	HBV	(Hepatitis	B	Virus)	and	HCV	(Hepatitis	C	
Virus)-induced	hepatocellular	 carcinoma	 (Waidmann,	Kronenberger	et	 al.	 2014).	 In	
addition,	aberrant	expression	of	IL-22R1	was	found	in	lymphoma	patients.	Compared	
to	normal	lymph	nodes,	primary	central	nervous	system	lymphomas	showed	higher	
IL-22R1	expression	(Sung,	Kim	et	al.	2011).	
	 	
In	 terms	 of	 the	 kidney,	 no	 publication	 was	 found	 in	 PubMed	
(http://www.ncbi.nlm.nih.gov/pubmed/)	in	respect	of	the	correlation	between	IL-22	
or	IL-22R	expression	and	RCC.	Only	one	study	focus	on	the	effects	of	IL-22	on	human	
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RCC	cell	 line	A498	 in	vivo	and	 in	vitro,	 showing	 that	 IL-22	suppressed	A498	cells	 in	
vitro	 and	 inhibited	A498	 cell-bearing	mouse	 xenografts	 (Zhang,	 Shang	et	 al.	 2011).	
This	 result	 seems	 to	be	 inconsistent	 to	our	 study.	 The	 result	 from	 the	other	 study	
implied	that	IL-22	might	play	an	anti-RCC	role	in	A498	cell	line	partially	mediated	by	
STAT1	signaling	pathway	regulation	as	well	as	G2/M	cell	cycle	arrest.	However,	our	
study	showed	that	IL-22	might	promote	the	progress	of	ccRCC.	One	explanation	for	
these	 different	 results	 is	 that	 different	 study	 objects	 were	 used.	 The	 biological	
behavior	of	tumor	cells	 is	not	always	consistent	between	cell	 lines	and	real	tumors	
from	patients.	Additionally,	IL-22	may	have	different	effects	not	only	in	cell	lines	and	
real	 tumors,	but	also	 in	different	phases	of	 tumor	progression.	What’s	more,	 IL-22	
may	play	different	 roles	 in	different	 cell	 lines.	 For	 instance,	because	 IL-22	plays	 its	
role	 by	 IL-22/IL-22RA1	 signaling	 pathway,	 the	 cell	 lines	 with	 more	 expression	 of	
IL-22RA1	 will	 have	 more	 IL-22	 effect.	 Thus,	 different	 cell	 lines	 should	 be	 used	 in	
further	studies	covering	this	subject.	 	
	
From	the	TCGA	results,	we	gained	knowledge	on	correlations	between	alterations	in	
IL-22/IL-22RA1	 expression	 and	 the	 outcome	 of	 ccRCC	 patients.	 Patients	 with	 high	
expression	 of	 either	 IL-22	 or	 IL-22RA1	 presented	 with	 shorter	 outcomes	 than	
patients	with	low	expression	of	 IL-22	or	IL-22RA1.	Based	on	the	varieties	of	studies	
mentioned	above,	we	measured	the	expression	of	IL-22	and	IL-22RA1	in	ccRCC	and	
to	 estimate	 their	 relationship	 with	 clinicopathological	 characteristics	 as	 well	 as	
prognosis	in	ccRCC.	Moreover,	the	study	of	TCGA	data	is	based	on	gene	expression,	
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and	 what	 we	 did	 next	 is	 to	 assess	 the	 effect	 of	 IL-22	 and	 IL-22RA1	 on	 protein	
expression	levels	from	Munich	ccRCC	patients’	cohort.	 	
	
From	the	results	of	immunohistochemical	staining,	IL-22	expression	was	detected	in	
the	 kidney	 cancer	 tissues.	However,	 it	 is	 not	 easy	 to	 figure	 out	where	 exactly	 this	
cytokine	 is	 located.	As	mentioned	above,	 IL-22	belongs	 to	a	cytokine	 family	 that	 is	
involved	in	tissue	homeostasis.	 IL-22	was	originally	found	to	be	expressed	in	T	cells	
of	both	human	and	mouse	(Dumoutier,	Louahed	et	al.	2000,	Wolk,	Kunz	et	al.	2002).	
In	humans,	the	main	producers	of	IL-22	are	innate	lymphoid	cells	(ILCs),	TH17	cells,	
and	TH22	cells,	particularly	at	mucosal	 surfaces	 (Duhen,	Geiger	et	al.	 2009,	Trifari,	
Kaplan	et	al.	2009,	Sonnenberg,	Fouser	et	al.	2011).	IL-22	is	produced	by	CD3+	(CD4-	
CD8-)	 oligoclonal T	 cells that	 are	 detected	 in	 epithelia	 of	 the	 organs	 mentioned	
above	(Bonneville,	O'Brien	et	al.	2010).	In	the	current	study,	the	expression	of	IL-22	
in	ccRCC	is	significantly	correlated	with	Fuhrman	grade,	primary	T	stage,	relapse	and	
vital	 status,	 which	 indicated	 that	 IL-22	 may	 impact	 the	 outcome	 of	 ccRCC.	 	
Kaplan-Meier	analysis	demonstrated	that	high	expression	of	IL-22	is	associated	with	
poor	 prognosis	 in	 ccRCC.	 However,	 multivariate	 analysis	 showed	 that	 high	
expression	of	IL-22	is	not	an	independent	prognostic	factor	of	either	overall	survival	
or	 disease-free	 survival.	 This	 result	 is	 not	 consistent	with	 some	 other	 studies.	 For	
instance,	 Zhang	Wen	 et	 al.	 demonstrated	 that	 IL-22	 is	 an	 independent	 prognostic	
factor	of	overall	survival	in	pancreatic	ductal	adenocarcinoma	(Wen,	Liao	et	al.	2014).	
Jiang	 et	 al.	 found	 IL-22	 to	 be	 overexpressed	 in	 human	 hepatocellular	 carcinoma	
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microenvironment,	which	might	 lead	to	tumor	growth,	 inhibition	of	apoptosis,	and	
promotion	of	metastasis	due	to	STAT3	activation	(Jiang,	Tan	et	al.	2011).	In	contrast,	
Kobold	 et	 al.	 did	 not	 observe	 a	 correlation	 between	 IL-22	 expression	 by	
immunohistochemistry	 and	prognosis	 in	 lung	 cancer,	which	 suggested	 IL-22	not	 to	
be	 a	 predictor	 for	 lung	 cancer	 patients	 (Kobold,	 Volk	 et	 al.	 2013).	 These	 findings	
indicate	that	the	predictive	role	of	IL-22	might	differ	between	different	organs.	 	 	
When	it	comes	to	the	therapeutic	role	of	the	IL-22/IL-22R	axis	 	 in	cancer	patients,	
no	 investigation	 has	 been	 performed	 so	 far	 One	 study	 established	
hepatocyte-specific	IL-22Ra1	knockout	(Il22Ra1Hep-/-)	and	Stat3	knockout	(Stat3Hep-/-)	
mouse	models	to	study	the	therapeutic	role	of	IL-22	in	experimental	intra-abdominal	
Klebsiella	 pneumonia	 infection	 in	 mice.	 They	 infected	 the	 mice	 with	 Klebsiella	
pneumonia	 that	 resulted	 in	 liver	 injury	 and	 necrosis,	 and	 the	 result	 indicated	 that	
IL-22	 overexpression	 or	 therapeutic	 administration	 of	 rIL-22	 (recombinant	 IL-22)	
reduced	 bacterial	 burden	 in	 both	 the	 liver	 and	 spleen,	 therefore	 IL-22	 may	 be	 a	
useful	adjunct	in	treating	hepatic	as	well	as	intra-abdominal	infections	(Zheng,	Horne	
et	al.	2016).	Moreover,	in	lung	cancer	cells	IL-22	acts	as	an	autocrine	factor	to	make	
cancer	 cell	 survival	 and	 resistance	 to	 chemotherapy.	 Meanwhile,	 this	 therapeutic	
effect	 was	 found	 in	 vivo	 in	 a	 xenograft	 model	 by	 IL-22	 RNAi	 (RNA	 interference)	
plasmids	(Zhang,	Chen	et	al.	2008).	There	are	many	other	studies	demonstrating	that	
IL-22	expression	was	positively	correlated	with	tumor	growth,	metastasis	and	tumor	
stages	(Jiang,	Tan	et	al.	2011).	
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Immunohistochemical	 staining	 for	 ccRCC	 tissues	 showed	 that	 IL-22RA1	 was	
expressed	at	 the	cell	membrane	and	 in	 the	cytoplasm.	As	we	know,	 the	 functional	
IL-22RA1	is	restricted	to	nonhematopoietic	cells	of	the	pancreas,	liver,	skin,	intestine,	
lung	and	kidney	(Wolk,	Kunz	et	al.	2004).	It	is	believed	that	immune	cells	are	not	the	
target	 cell	 of	 IL-22,	 monocytes,	 B	 cells,	 T	 cells,	 NK	 cells,	 monocyte-derived	
macrophages	 and	 dendritic	 cells	 do	 not	 express	 IL-22RA1	 (Wolk,	 Kunz	 et	 al.	 2002,	
Wolk,	Kunz	et	al.	2004,	Wolk,	Witte	et	al.	2008).	Both	IL-22RA1	and	IL-10R2	chains	of	
the	 IL-22	 receptor	 are	 expressed	 constitutively	 in	many	 organs,	 and	 epithelial	 cell	
lines	 derived	 from	 these	 organs	 respond	 to	 IL-22	 in	 vitro	 (Kotenko	 2002).	 The	
expression	of	 IL-22RA1	determines	the	sensitivity	of	 the	cells	 towards	 IL-22	 (Sabat,	
Ouyang	et	al.	2014).	IL-22	binds	to	its	receptor	chains	in	a	temporal	mechanism	and	
IL-22	correlated	with	the	extracellular	domain	of	IL-22RA1	(Li,	Tomkinson	et	al.	2004).	
IL-22	primarily	acts	on	epithelial	cells	to	perform	barrier	function	(Aujla,	Chan	et	al.	
2008).	Ligation	of	IL-22RA1	induces	migration	and	proliferation	of	epithelia	in	these	
organs,	 so	 that	 the	 barrier	 integrity	 is	 enhanced	 by	 molecular	 variation	 such	 as	
phosphorylation	of	STAT3,	activation	of	MAP	kinase,	and	activation	of	proliferative	
genes	like	c-Myc	and	cyclin	D1	(Xie,	Aggarwal	et	al.	2000,	Lejeune,	Dumoutier	et	al.	
2002).	 One	 study	 by	 Joseph	 Franz,	 et	 al.	 noted	 that	 IL-22RA1	 is	 shuttled	 for	
degradation	by	a	functionally	non-described	human	protein	named	FBXW12	(F-BOX	
and	WD	Repeat	Domain	Containing	12).	Increasing	FBXW12	may	suppress	IL-22RA1	
expression	and	IL-22	dependent	cellular	responses,	in	addition,	FBXW12	upregulates	
IL-22RA1	expression	level	and	signaling	(Franz,	Jerome	et	al.	2015).	
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In	 the	recent	study,	 IL-22RA1	seems	to	be	a	promising	prognosis	marker	 for	ccRCC	
patients.	Patients	with	a	high	level	IL-22RA1	expression	tend	to	have	shorter	overall	
and	disease-free	survivals,	and,	more	interestingly,	 IL-22RA1	can	be	regarded	as	an	
independent	 predictor	 of	 both	 overall	 survival	 and	 disease-free	 survival	 from	 the	
result	of	multivariate	Cox	proportional	hazards	regression	analysis.	This	conclusion	is	
consistent	 with	 the	 results	 from	 TCGA,	 which	 also	 suggests	 a	 potential	 role	 of	
IL-22RA1	 in	 ccRCC	 patients.	 Nevertheless,	 in	 the	 current	 study	 we	 only	 detected	
protein	levels	of	IL-22	and	IL-22RA1	expression	in	ccRCC	tissues,	hence	mRNA	levels	
of	 IL-22	 and	 IL-22RA1	 should	 be	 assessed	 as	 well,	 and	 further	 studies	 on	 the	
IL-22-IL-22R	 pathway	 and	 their	 mechanism	 in	 cancer	 are	 still	 necessary	 before	
clinical	application	of	our	findings.	
	
Several	 potential	 therapeutic	 options	 may	 exist	 to	 target	 the	 molecules	 in	
IL-22-IL-22RA1	system.	For	instance,	TNF	-specific	antibody	or	p40-specific	antibody	
can	block	cytokines	like	TNF	and	IL-23,	so	that	inhibit	the	activation	and	survival	of	T	
helper	cells,	as	reported	that	adalimumab	and	ustekinumab	can	be	used	in	psoriasis	
(Sabat,	Ouyang	et	al.	2014).	Antagonists	can	block	T	helper	cell-specific	transcription	
factors	 that	 promote	 IL-22	 production	 such	 as	 Ahr.	 Additionally,	 IL-22	 can	 be	
inhibited	 by	 antibodies	 or	 IL-22BP.	 Furthermore,	 antibodies	 targeting	 IL-22RA1	
(IL-22RA1-blocking-antibody)	 can	 neutralize	 the	 function	 of	 IL-22RA1	 by	 inhibiting	
the	 binding	 of	 IL-22	 to	 IL-22RA1.	 Moreover,	 inhibitors	 that	 target	 downstream	
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molecules	such	as	STAT3,	JAK1	and	TYK2	may	also	block	the	IL-22-IL-22RA1	pathway.	 	
The	use	of	 IL-22RA1	blocking	antibodies	 seems	 to	be	one	of	 the	most	appropriate	
therapeutic	 strategies	 for	 various	 reasons.	 The	 most	 convincing	 reason	 is	 this	
inhibition	 is	 highly	 specific	 in	 the	 IL-22-IL-22RA1	 system,	 so	 that	 very	 limited	
unwanted	effects	will	be	produced.	In	addition,	IL-22RA1	is	not	expressed	in	immune	
cells.	 Instead,	 it	 is	 only	 expressed	 by	 epithelial	 cells	 from	 several	 organs.	 This	
phenomenon	 makes	 it	 impossible	 to	 produce	 dominating	 systemic	 immune	
activation	 or	 inhibition	 (Sabat,	 Ouyang	 et	 al.	 2014).	 The	 possible	 pathway	 of	
IL-22-IL-22RA1	in	renal	cell	carcinoma	is	shown	in	figure	18.	
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Figure	18	IL-22-IL-22RA1	pathway	in	renal	cell	carcinoma.	IL-22	released	from	T	cell	binds	to	
IL-22RA1	 on	 renal	 cancer	 cell,	 leading	 to	 the	 activation	 of	 downstream	 IL-22RA1	 target	
genes.	
	
However,	there	are	limitations	to	the	conclusions	drawn	from	the	present	study:	
1. With	regard	to	the	TCGA	cohort	analysis,	no	multivariate	analysis	is	provided	to	
evaluate	 the	 independent	 prognostic	 significance	 of	 IL-22/IL-22R	 expression.	
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Further	no	data	regarding	the	duration	of	follow-up	or	the	number	of	events	in	
this	cohort	was	available.	
2. With	regard	to	the	Munich	cohort,	the	number	of	the	cases	might	be	too	limited	
(n=60)	to	provide	definitive	results.	 	
3. The	number	of	events	within	 this	 cohort	 is	 small	 (18	 recurrence	events	and	23	
deaths).	The	low	event	rate	hampers	the	ability	to	control	for	multiple	variables	
(Age,	 Sex,	 Grade,	 Stage,	 Necrosis,	 Venous	 Thrombosis,	 IL-22,	 and	 IL-22R)	 and	
might	lead	to	a	bias	in	the	statistical	results.	 	
	
Obviously,	evolving	data	suggest	 that	 inhibiting	the	activity	of	 IL-22-IL-22R1	system	
may	 be	 a	 therapy	 for	many	 diseases.	 Even	 though	 there	 is	 still	 a	 long	 way	 to	 go	
before	using	these	approaches	to	patients,	however,	we	should	keep	in	mind	that	it	
is	 a	 promising	 potential	 therapeutic	 option	 for	 IL-22-IL-22R1	 system-associated	
diseases.	IL-22RA1	status	may	act	as	a	prognostic	factor	potential	target	for	therapy	
to	overcome	drug	resistance.	
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